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Kauraka koutou i mate pīrau pēnei me au nei. E kāore! 
Me haere ake koutou i ruka i te umu kakara.  
Taku whakaaro i mate rakatira i ruka i te tāpapa whawhai. 
Do not die a rotting death like mine. No!  
Leave this world via the fragrant ovens of war.  
In my opinion a chiefly death occurs on the battlefield.  
Te Wera, Kāi Tahu 
This whakataukī comes from Te Wera, a Kai Tahu chief who warned his sons to die 
honourably on the battlefield and not slowly of natural causes, aka taking the easy route. In 
many ways, completing a PhD thesis on Indigenous quantitative research methodologies 
was my battlefield. I have no doubt it would have been a lot easier to build on the existing 
qualitative research experience of my Masters in Public Health, but no, I decided to take on 
the battlefield of quantitative research, with minimal experience. To be honest it has been 
an incredible mind shift that I couldn’t have achieved without my supervisors: Professor 
Suetonia Palmer, Professor Lutz Beckert and Professor Suzanne Pitama who supported and 
grounded me. They are what I consider research heroes and I am eternally grateful to them 
for their patience and expertise; without them this PhD would not have been completed. 
There were also others along the way who have guided this thesis; Professor Shaun Ewen 
from the University of Melbourne who provided a global critique not only of my writing, 
but also of my awareness of systems and structures that continue to colonise pedagogies; 
and, Dr Jonathan Williman, who rescued me multiple times when my statistical codes were 
not working and he would say, “insert a comma” and all would be corrected.  
 
Of course, there are also my life heroes who kept me grounded and just told me to get it 
finished, namely my husband Louie who is the most practical and supportive husband any 
wahine academic could ask for! My whānau who supported me in innumerable ways, from 
dog-sitting/baby-sitting, to reference checking; thank you. My two boys Jack and Tai who 
could recognise when Mum was stressed and would clean their rooms without being asked. 
Lastly, I would also like to take this opportunity to mihi to all those Māori patients and 
whānau who have endured chronic kidney disease. I hope that by analysing the data from 
these patients, this thesis will inform clinical practice and research to reduce health 













This thesis is dedicated to my Aunty Biddy and Nephew Michael who both passed away in 
2016, my Nana Molly Harrington who endured kidney failure as a young mother, and my 
Poppa Stanley Harrington who nursed Molly at home until her passing
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Glossary of Selected Māori Terms 
 
Kaupapa   Agenda, topic, theme  
 
Kaupapa Māori Research Kaupapa Māori Research KMR as a methodology emerged as a 
form of resistance to using research as a colonial tool. It 
challenges and critiques the way that research generates 




Māori The Indigenous Peoples of Aotearoa/New Zealand 
 
Mauri Ora Life force, Well-being 
 
Tino Rangatiratanga Self-determination, sovereignty, autonomy, self-government, 
control, power.  
 
Whakapapa Genealogy, lineage      
 
Whānau    Family group, extended family 
 
Glossary of Technical Terms 
 
ANZDATA  Australia and New Zealand Dialysis and Transplantation Registry 
CKD   Chronic kidney disease 
CONSIDER Consolidated criteria for strengthening the reporting of health research 
involving Indigenous Peoples 
HD   Haemodialysis 
MOU   Memorandum of Understanding 
MOA   Memorandum of Agreement 
PD   Peritoneal Dialysis 
KRT   Kidney Replacement Therapy 
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Chapter One: Introduction 
Article 1 
“Indigenous individuals have an equal right to the enjoyment of the highest attainable 
standard of physical and mental health. States shall take the necessary steps with a view to 
achieving progressively the full realization of this right.” 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
1.1 Introduction  
 
The principles of having the right to be equal to all other peoples, while recognising the right 
to be different, form the basis of the UN Declaration of the Rights of Indigenous Peoples.[1] 
Despite this acknowledgement that “Indigenous Peoples have an equal right to the highest 
attainable standard of physical and mental health”, health statistics illustrate this right has yet 
to be realised.[2-4] The Declaration establishes that human rights standards and freedoms 
must be applied within the context of Indigenous Peoples, including reversing the impact of 
colonisation on the socio-cultural health and well-being of many Indigenous nations. Failure 
to do so has seen health inequities persist despite considerable research and policy efforts.[5, 
6]  
 
Understanding Indigenous health inequities requires an equity lens to recognise the impact 
that colonisation and loss of cultural identity have on health and well-being. An equity lens 
enables a critical examination and understanding of systems and processes that entrench 
racism and embed inequity.  Inequity in the experiences and outcomes related to health and 
well-being experiences and outcomes for Indigenous Peoples has been a critical focus in 
health research for decades including population health research and genetic research.[7-10] 
More recently, two Indigenous researchers (2016), have led a global research team 
investigating the health of Indigenous and Tribal Peoples globally. Reporting on 23 countries 
and 28 different Indigenous populations they found evidence of inequities in health and social 
outcomes when Indigenous populations were compared with non-Indigenous populations.[3] 
This global study identified the need for global monitoring of Indigenous Peoples’ health 
status using Indigenous research methods and the inclusion of access to social determinants 
of health within analyses.  Anderson et al identified that global monitoring provided evidence 
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that national governments needed to develop targeted policy responses to Indigenous 
health.[11]  
 
When reflecting on the most appropriate methodologies to study Indigenous health, it is 
possible that Eurocentric research methods reinforce colonial power structures that sustain 
deficit theories, dehumanisation, loss of resources and marginalisation of Indigenous Peoples 
through policy and practice.[12-14] Indigenous critique of Eurocentric scientific research has 
been met by responses that include epistemicide, appropriation of Indigenous knowledges 
and publication bias.[15, 16] Non-indigenous research methodologies have consistently 
privileged observations that Indigenous health outcomes and experiences are caused by 
personal lifestyle choices and behaviour, with little to no recognition of the systemic and 
colonial genesis of Indigenous health inequities.[17]  
 
Colonisation is commonly defined as a process of power, that supports ongoing oppression 
and marginalisation of Indigenous within their nations.[14] Colonisation is historically 
understood as the acquisition of power through land and resources. In a contemporary 
context, colonisation remains a process of acquiring power and can be directly linked to 
capitalism. The ongoing impact of colonisation on the health and well-being of Indigenous 
populations internationally has been well documented.[2-4] In addition to the acquisition and 
utilisation of resources, colonisation also includes the appropriation and assimilation of 
Indigenous knowledge. This lack of acknowledgement or acceptance of Indigenous 
paradigms within the “space” of quantitative scientific rigour has led to quantitative research 
to become a tool of reinforcing colonisation, i.e. research that is deficit-based and reinforces 
and validates negative stereotypes of Indigenous Peoples.[12-14]  
 
Chronic kidney disease is defined as the “presence of structural or functional renal 
abnormalities, present for period greater than three months, with implications for patients 
health”.[18]  It causes the filtering function of the kidneys to decrease and is generally 
irreversible. Patients with long standing kidney disease will require at some point renal 
replacement therapy such as dialysis and/or kidney transplantation. Chronic Kidney disease is 
often described as a silent disease due to having no symptoms during the early stages of the 
conditions and the increased risk of a cardiovascular event in patients with untreated Chronic 
Kidney disease.[19]     
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Globally there are 370 million Indigenous Peoples.[20] It is widely understood that Chronic 
kidney disease disproportionally impacts Indigenous Peoples.[5, 21, 22] The projected global 
impact of chronic kidney disease is expected to reach 14 per 100,000 people by 2030, with a 
greater burden of disease and premature death among the Indigenous Peoples of America, 
Canada, Taiwan, Australia, Hawaii and Aotearoa New Zealand.[21, 23] An accepted 
explanation for inequitable outcomes is that increased rates of kidney disease for Indigenous 
Peoples are caused by higher rates of low birth weight, poverty, diabetes, hypertension and 
cardiovascular disease.[9, 24] Socio-economic deprivation and rural living are seen as 
contributing factors that lower life expectancy and increase chronic disease risk.[21, 25] 
However, factors leading to the lower rates of best practice treatment practices such as pre-
emptive transplantation and the suitability of home-based and rural/country/reservation 
centred disease management are less understood.  Indigenous research methodologies have 
the potential of widen our understanding of the root causes of sustained inequities, including 
differences in treatment practices and factors related to colonisation, to inform a greater 
understanding of inequity in the setting of chronic disease.[26]   
 
The principles and paradigms listed provide evidence-based practices to support exploration 
of inequity through decolonising methodologies and loss of understanding from Eurocentric 
practices. This thesis will employ the principles of the Declaration of the Rights of 
Indigenous Peoples, Te Tiriti o Waitangi and Kaupapa Māori Research Methodology to 
explore the sustained inequities experienced by Māori (the Indigenous Peoples of Aotearoa 
New Zealand) with CKD in Aotearoa New Zealand using chronic kidney disease as a case 
study.  The Kaupapa Māori approach employed in this thesis enables research practices to 
enact the principles of the Treaty of Waitangi. The Treaty of Waitangi is the foundational 
document of Aotearoa/New Zealand from 1840 defines the constitutional relationship 
between the Treaty partners, the British Crown and Iwi, the governing structures for Māori as 
the Indigenous Peoples of Aotearoa New Zealand.  In particular, the research process 
incorporates Article 3 of the Treaty that charges the British Crown with the responsibility to 
provide equity and therefore health equity for Māori, as a human right.[27]  
 11 
1.2 Background  
The ongoing impacts of colonisation on the rights and health of Indigenous Peoples globally, 
especially within settler colonies such as Australia, Canada, New Zealand and United States 
has been described and more critically challenged by Indigenous academics.[2, 17, 28, 29] It 
is well understood by Indigenous researchers that the root cause of health disadvantage 
experienced by Indigenous Peoples is colonisation.[30] However, the inclusion of 
colonisation as an explanatory causative factor of Indigenous Peoples health inequities in 
mainstream health research is variable.[31] As outlined previously in this chapter the process 
of acquiring power via tools of colonisation such as research continues to influence 
knowledges that are valued (Scientific/western), and disregard for Indigenous knowledges, 
particularly in the utilisation of quantitative data to inform health policy and perpetrate 
Indigenous Peoples health stereotypes.[32]  
Data is used to inform those in power who ultimately make decisions that have an impact on 
the wellbeing of societies.[33] The power in data portrayal of Indigenous Peoples is 
synonymous with the control and suppression of social and economic systems and structures 
within colonised nations.[33, 34] The identification of the use of data as a tool of colonisation 
has also identified the role that data plays in decolonization. Decolonisation is the process 
that refers to the challenging of experiences that have been driven by colonial agendas, 
including the hierarchy of knowledge, racism and epistemicide of Indigenous 
knowledges.[29] The process of decolonisation necessitates the principle of Tino 
Rangatiratanga (self-determination and sovereignty), and requires anti-racism tools that 
monitor and highlight the impact of systemic racism and colonization on the social, political, 
economic and cultural systems of Indigenous peoples.[32] Kaupapa Māori research 
methodology, Indigenous data governance, Indigenous data sovereignty and Indigenous 
quantitative methods are Indigenous frameworks that challenge the on-going impacts of the 
use of data as a colonising tool.    
 
The whakapapa of Kaupapa Māori Research Methodology, Indigenous data governance and 
sovereignty movements are based in the principle of the basic human right to equity.[27] The 
Indigenous data governance and sovereignty movements were further strengthened by the 
Declaration of Indigenous Peoples Rights, particularly in relation to the collection and 
utilisation of data relating to Indigenous Peoples.  The following section will provide a brief 
overview of the principles of Indigenous data governance, Indigenous sovereignty, 
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Monitoring of Māori health status, Māori inequities in Chronic Kidney disease, and the 
application of the principle of Tino Rangatiratanga to research.  
Indigenous Data Governance 
Indigenous data governance is defined as the kaitiakitanga (guardianship) of data by 
Indigenous nations in order to protect cultural knowledges and protect Indigenous ways of 
life for future generations.[35]Indigenous data governance has been defined as “as the right 
of Indigenous Peoples to decide what, how and why Indigenous data are collected accessed 
and used”.[36]  Indigenous data governance alludes to the Indigenous data sovereignty 
mechanism of the right to exercise control.[33]  Indigenous Data Sovereignty provides the 
catalyst for the reposition of data governance that reflects the Indigenous knowledges and 
visions.[37]  
Indigenous Data Sovereignty 
Indigenous data sovereignty is defined as the right of Indigenous Peoples to own, control, 
access and possess data that derive from them, and which pertain to their members, 
knowledge systems, customs or territories.[38] The first global publication related to 
Indigenous data sovereignty was published in 2016, and it built on the increasing number of 
Indigenous and non-Indigenous academics globally who voiced long held criticisms of the 
role of science as a tool of colonisation.[39, 40] Similarly, in 2019 a gathering of Indigenous 
and non-Indigenous academics met to discuss international law, Indigenous data sovereignty 
and the United Nations Declaration of Indigenous Peoples.[41] The agenda of this meeting 
was to establish the need for Indigenous data governance that ensured that decisions 
regarding Indigenous Peoples where guided by Indigenous values, and rights.[41] The 
foundational principles of equity preclude the importance of Indigenous data sovereignty as a 
mechanism to ensure global monitoring of Indigenous health outcomes through research that 
is responsive to Indigenous health need. Indigenous data sovereignty is a mechanism that 
underpins research practices that can address health inequities.  The Indigenous data 
sovereignty movement has placed a spotlight on the role of research as a colonisation tool.  
The principles of equity that form the basis of the Indigenous data sovereignty challenges 




In Aotearoa, discrepancies in the way that Māori data are collected and interpreted have 
formed the basis of critique by Māori and non-Māori researchers.[42-44] Hauora IV was 
published in 2007 and provided a discourse of how principles related to Indigenous Data 
Sovereignty can identify health inequities and inform health policy accurately, and inclusive 
of the influence of colonisation and racism.[4] All chapters in Hauora IV incorporate 
statistical methods that have been utilised in this thesis to highlight health inequities 
experienced by Māori patients with chronic kidney disease or kidney failure.  Te Mana 
Raraunga, The Māori Data Sovereignty Network in Aotearoa and the idea of a Māori Data 
Sovereignty Network was initiated at a workshop hosted by the Academy of the Social 
Sciences in Australia on Data Sovereignty for Indigenous Peoples July 2015.[45] This 
meeting led to the inaugural meeting on Māori Data Sovereignty in October 2015 and the 
establishment of Te Mana Raraunga.[45] Within this doctoral thesis the aspirations identified 
by Te Mana Raraunga, such as asserting Māori rights and ensuring quality and integrity of 
Māori data have been applied and adhered too. The following section introduces how 
principles of Indigenous data sovereignty and statistical analysis have been applied in this 
thesis.  
Monitoring Māori Health Status 
The way that health inequity is defined can have an influence on how health inequities are 
prioritised and monitored.[46] This doctoral thesis employs the definition of health inequities 
as “ differences in health that are not only unnecessary and avoidable but, in addition 
considered unfair and unjust.[47] The health status of Māori within Aotearoa New Zealand is 
similar to that among Indigenous Peoples around the world. Non-Māori experience better 
health when compared to Māori cross a range of life events and diseases. Non-Māori life 
expectancy for males (80.5 years) and females (83 years) remains markedly longer than for 
Māori males (73 years) and females (77 years).[27] This difference in life-expectancy is a 
measure of inequity. In health research, inequity is monitored by health research, often 
utilising large patient datasets or registries.  Māori academics have identified and critiqued 
national data sets that have influence over the way that Māori health inequities are portrayed 
and addressed through health policy.[26] This thesis endeavours to apply a similar critical 
lens to explore persistent inequities in chronic kidney disease through the analysis of a large 
dataset that is utilised to monitor outcomes in patients with chronic kidney disease and 
kidney failure.   
 14 
Māori Inequities in Chronic kidney disease   
Chronic kidney disease  has been chosen as the case study for this thesis to explore inequities 
in outcomes, using indigenous methodologies.  Māori experience CKD at three times the rate 
of non-Māori, non-Pacific New Zealanders.[22] Māori commence long term dialysis to treat 
kidney failure at three times the rate of New Zealand European adults.[5, 21, 48, 49] In 2015, 
New Zealand European adults incurred an incidence of dialysis nearly four times lower than 
that of Māori adults (72 versus 266 per million of population).[50] It is assumed that these 
disparate treatment rates are driven by comorbidity and socio-economic factors.[51] In 
contrast to the decreasing incidence of dialysis in non-Indigenous populations, dialysis rates 
for Māori have not declined over time.[5, 21, 48, 49] This thesis will use the principles of 
Kaupapa Māori Research, Indigenous data sovereignty and the United Nations Declaration of 
Indigenous Rights to explore CKD inequities.  
 
Historically, epidemiological research in CKD and Māori have focused on factors such as 
higher rates of comorbid disease, or higher rates of primary disease such as type 2 diabetes as 
the principal explanatory factors of current rates of CKD in Māori.[52, 53] The Australian 
New Zealand Dialysis and Transplant Registry (ANZDATA) in 2018 reported that in 
Aotearoa New Zealand, 70% of new Māori patients who commenced kidney replacement 
therapy between 2013 and 2017 had diabetic nephropathy as the primary cause of kidney 
disease.  However, these higher rates of primary disease and comorbidities, such as Type 2 
Diabetes, need to be understood within the contexts of colonisation and the impact of loss of 
land and economic resource on the health and well-being of Indigenous Peoples.[12, 54] The 
impact of colonisation on the health of many Indigenous Peoples globally may explain an 
increase of exposure to risk factors for chronic health conditions such as diabetes.  Loss of 
land, loss of language, loss of intergenerational wealth, and the impact of racism and 
migration all contribute to the overall well-being, and access to determinants of health.  
Understanding the upstream impacts on social economic and cultural determinants of health 
will provide a deeper understanding of current health inequities.[55]  
 
To identify root causes of inequities in chronic kidney disease, it is essential that researchers 
focus on not perpetuating health stereotypes, such as focusing on individual health 
behaviours. Researchers should critically reflect on the impacts of colonisation or systemic 
factors that negatively impact on health and well-being.[32] Research reporting prevalence, 
incidence, treatment practices and health outcomes remains a tool to monitor the response of 
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the health system to inequities in chronic kidney disease.[16] For example monitoring the 
treatment modalities in kidney failure may identify differences in treatment related to 
ethnicity alone. Differences identified can become a catalyst to explore, and explain causes 
for disparate outcomes, in particular why Māori experience higher rates of mortality and 
morbidity associated with chronic kidney disease.[56]   
Māori Health Research: Tino Rangatiratanga 
Many publications have described the state of health and well-being of Māori, and 
Indigenous Peoples more widely. The documentation and research of Māori health has 
spanned an evolutionary journey from the early writings concluding that Māori were a “dying 
race”, to contemporary research in partnership with or led by Indigenous researchers that 
identifies inequity and the impact of systemic racism and colonisation and research that 
provides solutions based on the concept of decolonisation and Tino Rangatiratanga. (Figure 
2) [12, 57] The process of research within Aotearoa New Zealand is slowly shifting from 
research being done “on” Māori to “in partnership” with Māori, or Māori-led. The 
development of Kaupapa Māori Research Methodology (KMR) and the increase in Māori 
health research and research capacity is contributing to a paradigm shift that is not only 
describing health outcomes; instead, it also focusses on the research process and its role in 
perpetuating Māori health disparities through research praxis using a colonisation lens.[29] 
This paradigm shift goes further than insisting that society and societal systems recognise the 
impact of colonisation on Indigenous Peoples. This positioning provides recognition of 
Indigenous knowledge, including the interpretation of research findings.[58] Kaupapa Māori 
Research methodologies also demand that Indigenous Peoples be the driver of change in 
research praxis as articulated in the Declaration of Rights for Indigenous Peoples.  
 
An example of a Tino Rangatiratanga approach is Te Tiriti ō Waitangi claim Wai 2575 (the 
New Zealand Health Services and Outcomes inquiry), which covers primary health care and 
mental health (including suicide and self-harm), and reports on stage one of the health and 
services outcomes inquiry.  This inquiry is investigating the impact of prioritisation, 
legislation, administration and funding of the primary care in Aotearoa on Māori health. 
Outcomes of the Wai 2575 tribunal review suggest a health-system-wide “reboot” inclusive 
of Māori health experts and professionals is required to co-design a primary health system 
responsive to Māori.  Epidemiological research is but one tool to monitor equity in health 
systems. A “reboot” in research tools may be necessary to critique Treaty partners and to 
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realise the principles of Te Tiriti including full health  and well-being for Māori and lifting 
Māori to full health and potential.  To address inequities, it is necessary to address colonial 
methodologies and to reduce their impact which sustain racism and inequities.[55] Research 
is a political act, and investigating Māori health inequities requires the inclusion of critical 
positioning.[55] Decisions about research methods including who to include, and how the 
analysis has been designed are based on often unarticulated values and assumptions which 
influence the findings and conclusions of the research. Interrogation of the assumptions 
underpinning research is required to identify the values driving research conduct. This 
includes exploring whether research methods themselves function as tools of colonisation to 
maintain inequities. Specifically, colonisation uses dehumanisation and racism to explain 
differences between Māori and non-Māori, and to drive a moral view that non-Māori are 
more deserving of health and well-being. The dehumanisation of Māori can be attributed to 
being a driving force which identifies individual behavioural factors as the explanation for 
health differences including in chronic kidney disease. Decolonisation of research requires 
that Māori health disparities are no longer explained by a singular factor like individual 
behaviours (for example the non-adherence, dietary patterns, or obesity). The root causes of 
inequity may derive from systemic factors related to colonisation such as political/legislative, 
resource-based, and multigenerational factors; they include racism, dehumanisation and 
marginalisation, at both individual and systemic levels.[55]  
 
Indigenous Data Governance, Sovereignty and Kaupapa Māori Research Methodology were 
developed as responses to the insidious impact of the colonisation and epistemicide of 
Indigenous knowledge systems.  The principle of Tino Rangatiratanga, which encompasses 
the foundational principles of Indigenous Data Governance, Sovereignty and Kaupapa Māori 
Research  Methodology has been applied to this doctoral thesis.   
1.3 Research Aim 
This thesis utilises Indigenous methods to investigate multifactorial causes of CKD 
inequities, including colonisation, racism and marginalisation. This thesis includes four 
analyses using Indigenous methodology, and aims to evaluate evidence of colonised practices 
with existing research. This thesis draws on decolonisation best practice to explore inequities 
and provides two examples of Tino Rangatiratanga research processes exploring inequities in 
CKD.  
The research aims include: 
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1. A systematic review with frequency analysis evaluating the practices and findings of 
existing epidemiological studies of chronic kidney disease involving Indigenous 
Peoples.  
2. A research reporting guideline to support researchers to develop a strength-based 
approach in health research involving Indigenous communities and participants. 
3. A retrospective cohort analysis exploring potential sources of inequity in dialysis-
related practices and outcomes in Aotearoa  New Zealand using Kaupapa Māori 
Research methodology and Indigenous statistical approaches.  
4. A retrospective cohort analysis exploring potential sources of inequity in kidney 
transplantation in Aotearoa New Zealand using Kaupapa Māori Research 
Methodology and Indigenous statistical approaches. 
The thesis concludes with recommendations for both research and clinical praxis.  
1.4 Thesis format 
This thesis is being presented as a hybrid thesis.  Four chapters are based on manuscripts that 
have been submitted to or published in peer-reviewed journals. These chapters are supported 
by the chapters of introduction, methodology, recommendations and conclusion. (Table 1) 
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Table 2 outlines the four publications including the PhD author contributions and publishing 
journals. The academic papers presented within this thesis are in publication format. 
 
Table 2 Publication list and author contributions 
 
Title of Publication Contributions Journal Citation PhD Chapter 
Current understanding of chronic 
kidney disease and Indigenous 
Peoples: A systematic review with 
meta-synthesis 
 
TH was the first author of this 
publication. Contributed to the 
conceptualisation of the 
research, compiled data, 
completed data extraction and 
synthesis, coordinated other 
authors, completed drafts 
including final draft of the 
manuscript.  
Accepted for Publication BMC 
Public Health June 2021.  
Chapter Three  
Consolidated Criteria for 
strengthening reporting of health 
research involving Indigenous 
Peoples: The CONSIDER 
statement. 
TH was the first author of this 
publication. Contributed to the 
conceptualisation of the 
research, compiled data, 
completed analysis and 
coordinated other authors, 
completed drafts including final 
draft of the manuscript.  
 Huria T, Palmer SC, Pitama S, 
Beckert L, Lacey C, Ewen S, Smith 
LT. Consolidated criteria for 
strengthening reporting of health 
research involving indigenous 
peoples: the CONSIDER statement. 
BMC Medical Research 
Methodology. 2019 Dec 
1;19(1):173. 
Chapter Four  
Inequity in dialysis related practices 
and outcomes in Aotearoa/New 
Zealand: a Kaupapa Māori analysis 
TH was the first author of this 
publication. Contributed to the 
conceptualisation of the 
research, compiled data, 
completed data analysis, 
coordinated other authors, 
completed drafts including final 
draft of the manuscript. 
Huria T, Palmer S, Beckert L, 
Williman J, Pitama S. Inequity in 
dialysis related practices and 
outcomes in Aotearoa/New 
Zealand: a Kaupapa Māori analysis. 
International Journal for Equity in 
Health. 2018 Dec 1;17(1):27. 
Chapter Five 
Equity in access to kidney 
transplantation in Aotearoa/New 
Zealand: A Kaupapa Māori 
approach.  
TH was the first author of this 
publication. Contributed to the 
conceptualisation of the 
research, compiled data, 
completed data analysis, 
coordinated other authors, 
completed drafts including final 
draft of the manuscript. 
Prepared for submission to Journal 




1.5 Chapter Conclusion 
This chapter has articulated the Indigenous positioning of this thesis. The United Nations 
Declaration of the Rights of Indigenous Peoples and Te Tiriti ō Waitangi clearly state that 
health equity is a basic right of Indigenous Peoples and should form the basis of action in 
health services and research. This thesis is grounded in demonstrating Tino Rangatiratanga 
within research praxis and demonstrates the application of Kaupapa Māori Research to 
quantitative research.   
 
This thesis uses chronic kidney disease as case study to explore and investigate inequities in 
health outcomes from an Indigenous methodological viewpoint, with critical appraisal of the 
role of research as a colonisation tool that impedes understanding of health inequity. The 
thesis explores and enacts Indigenous research praxis, such as Indigenous Data Governance 
and Sovereignty to assert Indigenous rights and provide a deeper understanding of the 
sources of inequity in Indigenous health outcomes using Hauora Māori and chronic kidney 
disease as a case study. The systematic literature review in Chapter three provides a  
summary using the Williams Framework to explore what is  reported as the causes of 
inequities among Indigenous Peoples with chronic kidney disease.[59]  Chapters five and six  
apply Indigenous quantitative methods, grounded in Kaupapa Māori Research Methodology 
and Indigenous data sovereignty principles to explore inequity in practice patterns related to 
dialysis and access to kidney transplantation.  
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Chapter Two: Methodology 
Article 2 
Indigenous Peoples and individuals are free and equal to all other peoples and individuals 
and have the right to be free from any kind of discrimination, in the exercise of their rights, in 
particular that based on their Indigenous origin or identity. 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
2.1 Introduction  
The United Nations Declaration of the Rights of Indigenous Peoples asserts the right of 
Indigenous Peoples to be free from discrimination.[1] The role of research within health is to 
provide empirical evidence that informs decision-making related to the structure and design 
of health systems and policies to address discrimination, allocate resources and funding, and 
avoid perpetuating inequities. [55] Research over the decades has not always considered the 
presence of colonial theoretical underpinnings to research questions, resulting in methods and 
findings that reinforce deficit-based framing, negative stereotypes and discrimination of 
Indigenous Peoples.[13]  Specifically, quantitative methods have utilised statistical databases 
and used methodological approaches which have positioned Indigenous Peoples’ values and 
behaviours as the cause of health inequities.[15] 
 
Eurocentric research has privileged epistemological beliefs that locate non-Indigenous as the 
hegemonic norm, without considering the impact of colonisation on the social, cultural and 
economic well-being of Indigenous Peoples.[15] The privileging of epistemological beliefs 
(knowledges) from a perspective of western Eurocentric science, has meant that the “power” 
of knowledge is positioned within “white” norms. The epistemicide of Indigenous knowledge 
and lack of acknowledgement or acceptance of Indigenous paradigms within the “space” of 
quantitative scientific rigour has led to quantitative research being utilised to promote and 
sustain a colonial agenda.  The use of scientific methods as a colonising tool has resulted in 
the failure to address Indigenous health inequities, as evidenced by ongoing health inequities 
experienced by Indigenous Peoples globally.[14]  Existing scientific methodologies are able 
to frame inequity as a deficit present within Indigenous Peoples and, as such, may not enable 
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researchers to observe or consider how systemic advantages are sustained for non-Indigenous 
populations within health services.[16] Statistical portrayals of Indigenous Peoples’ health 
and well-being are used to place Indigenous Peoples as the “other, dysfunctional, unhealthy” 
and non-Indigenous as the hegemonic norm – without requiring consideration for the societal 
impact of colonisation on the social, cultural and economic well-being of Indigenous 
Peoples.[15] Recent global events have highlighted that Indigenous and minority populations 
are intolerant of the ongoing impact of racism and colonisation on their basic human rights to 
be free of discrimination. Never has there been a more pertinent time to scrutinize “white-
washing” of health research.[17] 
 
Given sustained inequity in health outcomes for Māori in Aotearoa New Zealand, this thesis 
has applied Indigenous research practices and accounted for sociodemographic and clinical 
factors to explore sources of inequitable treatment and outcomes for Māori with chronic 
kidney disease.[11, 60] Utilising Kaupapa Māori Research methodology within the 
quantitative research paradigm a priori identifies that the research conducted in this thesis 
embodies Tino Rangatiratanga over quantitative research paradigms to enact Indigenous data 
sovereignty. Tino Rangatiratanga translates as self-determination, and within a research 
context Tino Rangatiratanga is the embedding of Indigenous knowledges to inform research 
praxis. This can be demonstrated in research prioritisation, methods, analysis and 
dissemination.  This thesis presents four analyses that have applied Indigenous 
methodologies to examine health disparities from a Tino Rangatiratanga positioning, using 
chronic kidney disease as a case study to investigate how health disparities are perceived and 
perpetuated within epidemiological science.   
 
This chapter introduces Kaupapa Māori Research methodology, including a historical 
account of the origins of Kaupapa Māori Research (KMR), and a description of the 
application of KMR methodology to the four projects that contribute to this thesis.  
2.2 Kaupapa Māori Research  
This section will explore the foundations of Kaupapa Māori Research methodologies, 
including the application of the principle Tino Rangatiratanga (self-determination) to this 
doctoral thesis.  Kaupapa Māori Research as a methodology was developed in the 1990’s to 
explore barriers to Māori achievement within mainstream school environments and to 
identify factors that contributed to Māori educational success.[29] Kaupapa Māori Research 
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provides a framework to ensure Māori narratives, responses, beliefs and experiences are 
validated and that the equity of these experiences remains the core purpose of the research. 
Smith and others articulated that Māori had long been a fascination of researchers. Kaupapa 
Māori Research is a proactive stance that repositions  research being “done to Māori” to 
research that is in partnership “with” or “led by” Māori.  This in turn shifts the power from 
those being researched to becoming researchers and the responsibilities associated with the 
retrieval of an Indigenous space in research.[29]  
 
Kaupapa Māori Research encourages Indigenous and non-Indigenous researchers to explore a 
series of questions as a quality check to ensure that their research actively works to promote a 
decolonised agenda. These items were formulated to ensure the safety of the participants, but 
also the safety of Māori communities and their knowledge. [60] Kaupapa Māori Research is a 
direct response to colonisation in Aotearoa.[61]  Kaupapa Māori Research provides a 
framework to implement a structural analysis that identifies the impact of inequities of access 
to determinants of health.[61]  Over the past 20+ years, Kaupapa Māori Research has been 
applied progressively within health research environments, identifying the need for 
accountability of the health system to address issues of health equity, as well as aligning and 
monitoring the Crown’s obligations under te Tiriti o Waitangi and the equity principles of the 
United Nations Declaration of the Rights of Indigenous Peoples. [1] [4] As Māori research 
capacity has increased, so has the capacity for Māori researchers to direct and initiate 
research projects, as principal investigators with research questions founded in Kaupapa 
Māori Research philosophy. 
 
Given that health research contributes substantially to the empiric basis on which health 
services are prioritised, planned, designed and funded, significant questions have been raised 
as to how research findings based on dominant cultural norms can inform effective health 
care for individuals, whānau, hapu, and populations that are inadequately represented within 
that research [55]. This is why the application of Kaupapa Māori Research principles to 
quantitative research methods is crucial in ensuring meaningful research outcomes that 
represent Māori within the Aotearoa New Zealand health system. [56, 60, 62, 63] The 
following section describes the practical application of Kaupapa Māori Research principles, 
including the principle of Tino Rangatiratanga to current monitoring of Māori health status. 
As well as provided examples of how the principle of Tino Rangatiratanga was applied to this 
doctoral research.  
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2.3 Indigenous Research / Tino Rangatiratanga 
 
In order to achieve equity, there is the requirement for data sets and quantitative methods to 
validate the Indigenous voice and ensure that data informing decisions and policies portray 
the “true” story. [3, 4, 30, 44] The Kaupapa Māori Research approach that has been 
employed to guide this thesis has enabled research practices to enact the principles of Te 
Tiriti o Waitangi and the United Nations Declaration of the Rights of Indigenous Peoples. 
[60, 64] Key principles of both Te Tiriti o Waitangi and the United Nations Declaration of 
the Rights of Indigenous Peoples charge the Crown in Aotearoa New Zealand with the 
responsibility to provide full health for Māori as a basic human right.  
 
The role of quantitative research is to provide information that definitively tests a hypothesis 
grounded in prior research and source data. As with many aspects of governance, 
methodology and processes that oversight societal and academic activity, the same scientific 
rigour has been employed over many years to privilege non-Indigenous resources and 
perspectives to entrench colonisation in health services research and evaluation. The 
application of Kaupapa Māori Research methodology to quantitative research utilises 
quantitative methods as a decolonising tool and promotes and centres Indigenous knowledge. 
As outlined in Article 23 of the Declaration of the Rights of Indigenous Peoples, Indigenous 
Peoples have the right to determine and develop strategies for Indigenous development. 
Decolonising data analysis and reporting is a powerful method of addressing inequities. 
 
In accordance with Kaupapa Māori Research principles, both the author of this thesis and one 
of the thesis supervisors are Māori. The Rāpaki branch of the Māori Women’s Welfare 
League identified prioritisation of research involving Māori and chronic kidney disease in 
2009. This resulted in the funding of a summer research project investigating Māori 
experiences of CKD which, coupled with known inequities in CKD, validated the 
prioritisation of future research exploring CKD in Māori populations.[65]  The following 
sub-sections describe how Kaupapa Māori methodologies informed research decision-
making, and include the critique of data identification within the ANZDATA dataset.    
Critique of Ethics and Research Guidelines for working with Indigenous Peoples 
The CONSIDER statement (chapter four) was developed as an output of this thesis through 
the identification of the lack of reporting of ethics and research principles that incorporate 
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and support partnerships with Indigenous communities in the existing published literature 
exploring CKD and Indigenous Peoples.  Using a Kaupapa Māori Research lens, this critique 
developed into the synthesis of available ethics and research guidelines into a checklist that 
supports Tino Rangatiratanga and Indigenous research leadership and partnership.  Through 
this Kaupapa Māori process the subsequent dialysis and transplant cohort studies associated 
with this thesis (chapters 5 and 6) were able to report findings that were inclusive of Kaupapa 
Māori principles.  
Ethnicity identification and collection.  
In Aotearoa, the statistical representation of Māori has been, and continues to be, heavily 
influenced by colonial interests with regard to policy and non-Indigenous New Zealand’s 
perceptions of Māori. The way that Indigenous data is collected and represented in the health 
system has a major impact on how services are resourced and developed. As discussed in 
chapter 1, Māori and non-Māori academics (who conduct Māori-responsive research) have 
identified systematic limitations in the statistical methods within the health system in regard 
to identification and collection of ethnicity data among Indigenous Peoples.[42, 43] The 
misrepresentation of Māori within data and analyses leads to under-representation, under-
reporting and deficit framing of Māori inequity and the determinants of inequity. As Reid 
stated, Māori are “dying to be counted”.[66] This phenomenon impedes the use of statistical 
analyses to inform health services and policies that support the development of appropriate 
health services to improve and sustain health and well-being for the whole population.  The 
census plays a crucial role within Aotearoa/New Zealand in providing accurate population 
information.  
 
The Aotearoa census is a tool to support governance and policy making by providing a 
population snapshot.  An Indigenous perspective of the potential value of the census is 
similar, and the Indigenous perspective is also mindful historically the impact of not being 
counted.[67] Aotearoa has a history of census. Subsequently there is also a history of how 
Maori have been “classified”. The historical influence of changes to census delivery, 
ethnicity classification and ultimately how Māori are classified and counted continues to have 
influence over the way Māori are represented within health datasets.[68] Kaupapa Māori 
Research enables a rights-based approach to epidemiology that centralises the right to Māori 
health equity.[68] The consequences of the continual colonisation of ethnicity identification 
within quantitative research results in misclassification and misrepresentation of Māori health 
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status. Most recently the change to an online census format in 2018 led to widespread 
criticism of the policy implications of the lower Māori response rates and particularly the 
calculation of mortality, morbidity and fertility rates, that inform national decisions based on 
census data such as housing, education and health.[69]  
Annually the National Renal Advisory Board produces an advisory report to the New 
Zealand Ministry of Health using the Australia New Zealand Dialysis and Transplant 
Registry data.[70]  The report uses the New Zealand census ethnicity data as the denominator 
information.  This ensures that the reporting of the status of kidney health in Aotearoa by 
ethnicity is reported accurately.  The utilisation of the New Zealand Census in this way has 
off set the possible misclassification of Māori within the ANZDATA Registry. (see chapter 
2) Likewise in this thesis ethnicity analysis was completed utilizing current ethnicity data 
protocols, including ethnicity sensitivity analysis. (Chapters 4 & 5)     
Marmot et al recommended that addressing methods employed to measure social and health 
outcomes is critical to addressing inequities.[71] In Aotearoa, appropriate recognition of 
Indigenous Peoples in data collection, research and audit is required to hold Crown and 
government agencies accountable, and also to create an informed space where organisations 
can respond to inequities appropriately. Within Aotearoa, the focus on accurate ethnicity data 
has been identified as a priority by Kaupapa Māori Researchers and increasingly understood 
by non-Indigenous researchers including the Crown through the New Zealand Ministry of 
Health.[72] Protocols have been developed to ensure consistency in ethnicity data collection 
across multiple social and health arenas.[72] In recognition of the Treaty partners and this 
obligation, we defined the comparative study cohorts in the primary analysis as Māori and 
non-Māori. Aligned with the United Nation Declaration on the Rights of Indigenous peoples, 
we included Māori as Peoples who self-identified as Māori and who live in Aotearoa New 
Zealand.[1] 
 
As outlined by Walter et al, the application of Indigenous methodologies to quantitative 
research is not purely about the research being completed by an Indigenous person, nor is it 
just about the interpretation of the research.[16] The application of Indigenous methodology 
requires constant monitoring of statistical analysis and portrayal of Indigenous data and plays 
a crucial role in the Indigenous production and critique of quantitative studies. The 
methodology for ethnicity documentation in the ANZDATA registry is an example of the 
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way that Indigenous data are portrayed in clinical quality registries and implications for 
analysis. ANZDATA has until recently defined ethnicity as “racial origin” and lists 
Caucasoid, Australian Aborigine, Chinese, Māori, Cook Islander, Samoan, Tongan, Torres 
Strait Islander, etc. On application to ANZDATA, it was identified that there was 
incongruence with the way that ethnicity data was collected for the ANZDATA data set and 
best-practice ethnicity data collection that aligns with KMR methodology 
 
The critique of ANZDATA categorisation of ethnicity is twofold. First, the use of the term 
racial origin as opposed to ethnicity is an example of how statistical classification continues 
to control how Indigenous Peoples are defined, and how that supports ongoing colonial 
control over large data sets. The ‘colonial control’ eludes to the use of the term ‘racial’, as a 
derivative of race, which in basic terms, is classification based on a set of physical 
characteristics such as skin colour that is based on a 19th century social ascription that implies 
biological difference and inferiority.[73] This is problematic in that this implication of 
biological difference feeds into stereotypes of inferiority of all those who are not of European 
descent or who do not ‘look’ European.   
 
As outlined by , the use of terms such as Caucasoid (as mentioned above as a classification 
used by ANZDATA) is an outmoded theory of racial distinction and does not align with New 
Zealand ethnicity data collection protocols. [74] As a response to this critique, ANZDATA 
has amended its collection terms regarding a patient’s identity. Whilst it is still not aligned 
with Statistics New Zealand’s best practice guidelines, the terminology is being reviewed to 
align better with New Zealand ethnicity data collection best practice. (Appendix 4) Within 
this thesis terminology was aligned with New Zealand Ministry of Health ethnicity 
guidelines.  Second, patients do not complete the ANZDATA survey. Therefore, the ethnicity 
of Indigenous patients in ANZDATA may not be self-identified. This is problematic from a 
Kaupapa Māori Research perspective as self-identification is a decolonising tool.[74] This 
leads to further issues identification issues as you cannot have more than one ethnicity 
identified in ANZDATA. 
Application of Indigenous quantitative methodology  
As outlined in the previous chapter, Indigenous data sovereignty and statistical methods that 
incorporate Indigenous research principles are crucial to supporting understanding of 
influential factors that perpetuate health inequities experienced by Indigenous Peoples 
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globally.  Kaupapa Māori Research methodology ensures that Māori praxis are valued and 
central to research practice. Kaupapa Māori Research has traditionally been employed in 
qualitative research practices.[75] More recently, scholars have reported methods to employ 
Indigenous methodologies in quantitative research.[16]  Existing scientific methodologies 
frame inequity as a deficit present within indigenous peoples and, as such, may not enable 
researchers and healthcare providers to observe or consider how systemic advantages are 
sustained for non-indigenous populations within health services.[56] However the use of 
Kaupapa Māori Research, specifically the principle of Tino Rangatiratanga supports the 
exploration of how the statistical analyses can be utilised to identify persistent systemic 
advantage within the health system, that cannot be explained by biological, cultural, social or 
cultural differences. The following sections provide examples of how the principle of Tino 
Rangatiratanga was applied to the use of  statistical methods within the context of this 
doctoral research.   
Propensity score matching 
Propensity score matching is a statistical method to analysis observational data by matching 
variables such as age, smoking status to estimate the effort of a treatment or intervention.  
Propensity score matching is used to reduce the effect of statistical bias within cohort studies 
and allows for analysis of observational studies that can mimic some of the characteristics of 
a randomised control trial.[76] Propensity score matching as a technique in observational 
studies aligns with Kaupapa Māori Research as it allows for the identification of difference in 
outcomes associated with ethnicity. Propensity score is a tool that can minimise residual 
confounding.[76]  Propensity score matching technique was applied to the analysis in 
Chapter 5 to test the hypothesis of whether there was a difference in dialysis practice 
patterns, even when clinical and socio-economic variables were accounted for.  
Indigenous age standardisation 
Indigenous age standardisation is a method of age standardisation that recognises the specific 
demographic age structure of Indigenous Peoples compared with non-Indigenous 
populations. Epidemiological studies that compare groups over time to examine trends use 
age standardisation as a practice of highlighting differences between groups, even when they 
have been adjusted.   The method most used is direct age standardisation where a 
standardised age structure was applied to a specific study cohort. The standard age structure 
from a common population is applied to all exposure cohort groups, to enable comparisons 
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adjusted for age (and therefore other age-related characteristics). The SEGI standard 
population and World health organisation standard population (WHO) population are the 
standard population models. [77] 
 
The SEGI population was devised in the late 1950s, based on 46 ‘European’ female and male 
populations reference. The World Health Organisation (WHO) standard is a more recent age 
standard that is based on the world population estimates from the year 2000–2025.[44] Figure 
1 illustrates the differences between the population profiles, with the Māori and SEGI age 
structure standard most similar, and the WHO and non-Māori population age-structures most 
closely aligned. The choice therefore of standardised populations has an impact on rates, 
which are used to measure inequity.  
 
Figure 1  Comparison of age standardisation population profiles 
    
 
Figure sourced from Robson B, Purdie G, Cram F, Simmonds S. Age standardisation–an indigenous standard? 
Emerging themes in epidemiology. 2007;4(1):3. The Figure provides a comparison of the Māori population 
profile to both the Non-Māori population profile and the profile of the populations used for aged 
standardisation (SEGI and WHO) 
 
While the Māori population is representatively more closely aligned with the SEGI age 
standardisation, SEGI still does not accurately reflect the Māori population demographic. 
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Robson (2007) stated that there was a requirement for studies to recognise that this can 
potentially lead to underreporting of mortality rates, rate ratios and rate differences.[77] 
Within this thesis the Māori population was used as the age standardisation population for all 
age standardisation.[44] Within the quantitative analyses reported in Chapters 5 and 6, the 
cohort populations of Māori and non-Māori were standardised to the Māori population, which 
provides more closely approximate Māori rates that could be provided by other standardised 
populations, due to the young Māori population.[78] 
Indigenous as the reference cohort 
In this thesis, Indigeneity is used as a “principle” within the analysis. Indigeneity, when 
considered as a principle, enables being Māori to be analysed as a marker of risk (for 
example, risk of exposure to colonisation, poverty, and institutional racism), as opposed to 
Indigeneity as a determinant of health practices and outcomes in themselves [16]. This is an 
important method of Tino Rangatiratanga and Indigenous data sovereignty, reducing the 
“othering” of being Indigenous within biomedical health status, to being the “norm”. In this 
thesis, this method was used within methods, results and interpretation of findings to avoid 
the Indigenous population being identified as having “deficit”. Using this methodology, the 
non-Indigenous cohorts are identified as experiencing privilege within the health system, 
such as higher survival or higher access to best practice medical interventions. For example, 
instead of Māori being more likely to die with higher rates of comorbid disease, the discourse 
is “flipped” and privilege is identified within the non-Māori population during the 
descriptions of the analytical results and interpretations.  
Multi-state, competing risk analysis. 
The consideration of appropriate statistical methods is vital in enabling accurate reporting on, 
and to hold health systems accountable for, current health status of Indigenous Peoples.[32] 
A multi-state model is used to model participants’ transition from one state to the next, e.g. 
survival to death.[79] Multi-state survival analysis demonstrates that potential hazards can 
change over time, e.g. comorbidities. It has been established that Indigenous Peoples have 
greater exposure to risk factors associated with disease as an outcome of the impact of 
colonisation.[3] Therefore statistical modelling needs to represent the impact of structural 
drivers such as racism and colonisation on Indigenous health. Likewise, completing risk 
analysis is defined as an event that precludes the occurrence of  the primary event of interest. 
[80]The competing risk of death was applied to the statistical analysis describe in chapter 6,  
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that explores equity of access to transplantation.  Competing risk analysis can provide 
information regarding response to treatment in terms of the disease process (in this case 
kidney disease) and non-disease related causes (Indigeneity).[81] The utilisation of these 
types of statistical methods that recognise that influences on health may differ between 
cohorts, is invaluable in understanding the impacts of colonisation on the health and well-
being of Indigenous Peoples.[26] 
Incorporation of Methods to Identify the Impact of Colonisation and Basic Causes of 
Health Inequities on Māori Health.   
The acknowledgement of the impact of social determinants of health and basic causes of 
disparities is well understood, however, the accounting for these influences in health research 
is less visible. [59, 71, 82, 83] This thesis (chapter 3) has utilized the Williams framework of 
basic causes of health disparities to identify basic causes of health inequities that currently 
well reported and underreported in CKD and ESKF research.  In utilising the Williams 
framework, it was identified that within literature investigating Indigenous Peoples and CKD 
and ESKF biological factors were well understood.  The challenge from a Kaupapa Māori 
methodological perspective is to firstly identify what is understood about inequities and 
subsequently highlight influences that were less understood, including the impact of 
colonisation and racism. Subsequently the quantitative research projects associated with this 
thesis (chapters 5 and 6) incorporate variables, such as NZDep13 and highlight the possibility 
of the influence of racism as an explanatory factor of different outcomes and clinical care 
pathways experienced by Māori patients and whānau.  
New Zealand Deprivation Index  
Marmot identifies that in order to reduce health inequity there must be action to reduce 
socioeconomic and other inequalities (material, social, political and cultural).[84] In order to 
address socioeconomic disparities, inequitable access to the determinants of health must be 
measured. Health inequities experienced by Māori communities and whānau are often 
explained by social and economic deprivation measured by access to identified determinants 
of health.  The monitoring of deprivation measures affords Māori and non-Māori researchers 
the ability to monitor the Crown’s action or inaction towards Māori access to the basic social 
determinants of health and well-being.[17] The measurement of New Zealand trends of 
determinants of health consist of data obtained via the census (in this case NZ Census 2013) 
and the New Zealand deprivation scale (NZDep2013) which measures the social 
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determinants of health, which included income, employment, access to communication and 
transport and home ownership. (Table 3) 
 
Table 3 NZ Deprivation dimensions with variable descriptions. 
 
Table sourced from: Atkinson J, Salmond C, Cramption J. NZDep2013 Index of Deprivation. Department of 
Public Health, University of Otago, Wellington: Division of Health Sciences, University of Otago; 2014. 
Measuring the social determinants of health in this way provides a detailed exploration of 
access to determinants and the ongoing impact on health outcomes. It is internationally 
understood that wider social, economic and political factors have a huge influence on the 
health and well-being of populations. [71] These wider influences manifest in the burden of 
disease on a population.[27] The NZDep13 scores were developed with three specific aims: 
1. Application to funding formula for health and policy purposes 
2. Application to research in a variety of settings  
3. Application of the scale by community-based groups to describe the communities 
they serve.  
Currently the latest version is NZDep13; when applied to Non-Māori and Māori populations 
the trend from previous years remains the same. Non-Māori are more likely to live in the 
least deprived areas of Aotearoa and suffer from a lower burden of disease (Figure 3). The 
value of understanding trends in access to determinants of health for Kaupapa Māori 
Researchers is that it allows for adjustment of statistical models to account for differences in 
access to the social determinants of health.  This becomes an important tool within 
Indigenous quantitative methods, as it provides evidence that if inequities are still present, 
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after adjusting for deprivation that there are other influences within the health system that 
need to be explored in order to explain persistent health inequities.[27] There are limitations 
to NZDep calculations, mainly that the NZDep measures areas as opposed to people; 
however, it remains a valuable tool for Indigenous researchers to hold social systems 
accountable for continuing inequity.[85] In this thesis the NZDep levels were included in the 
analysis investigating inequities in dialysis treatment to provide a level of analysis that 
accounted for socio-economic status as a possible explanatory factor. (Chapter 4)  
Figure 2  Neighbourhood deprivation distribution (NZDep13), Māori and non-Māori 
         
Source from : Ministry of Health. Tatau Kahukura: Māori Health Chart Book 2015 (3rd edition). . Wellington: 
Ministry of Health; 2015. This figure describes the deprivation distribution for Māori and non-Māori. 
2.4 Ethical Approval 
In accordance with University of Otago research protocols, consultation for the research was 
sought through the University of Otago, Christchurch (UOC) research office, including the 
Research Manager, Māori (Appendix 1). Ethical approval was provided by the University of 
Otago, Human Ethics Committee for the analyses reported in Chapter 4 and Chapter 5 
(HD14/27) (Appendix 2).  
 
In accordance with ANZDATA ethics protocol, this approval was required prior to 
ANZDATA release of data. ANZDATA has an internal ethics process that includes patient 
information regarding standard data collection (Appendix 3).  Likewise, the permission to 
reproduce the published material aligns with the Creative Commons Attribution (CC-BY) 




Methodological positioning is an important consideration within research. Within this 
chapter, the epistemological framework of Kaupapa Māori Research methodology used 
within this thesis was described. The chapter describes how specific statistical techniques 
enact Tino Rangatiratanga principles to investigate health inequity experienced by 
Indigenous Peoples. Applying Kaupapa Māori methodology to the research led to guidelines 
that align with ethical principles of research when working with Indigenous Peoples. This 
application enabled the exploration of practice patterns related to chronic kidney disease 
accounting for the impact of colonisation through methods supporting Tino Rangatiratanga.  
 
Chapter Three consists of a systematic literature of quantitative studies that describes 
reported sources of health inequities in Indigenous Peoples with chronic kidney disease. The 
systematic literature review utilises David Williams framework for studying racial 
differences to analyse the reported sources of health inequities in chronic kidney disease and 
end stage kidney failure.   
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Chapter Three: Systematic Literature Review 
 
Article 15 
States shall take effective measures, in consultation and cooperation with the Indigenous 
Peoples concerned, to combat prejudice and eliminate discrimination and to promote 
tolerance, understanding and good relations among Indigenous Peoples and all other 
segments of society. 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
3.1 Background 
This chapter is based on the paper titled “Reported sources of health inequities in Indigenous 
Peoples with chronic kidney disease: A systematic review of quantitative studies” as an 
outcome of this PhD. This paper has been submitted for publication in BMC Public Health 
Journal.  This chapter uses the formatting of the publication. Tables and figures appear at the 
end of this chapter. 
3.2 Introduction  
 
The United Nations Declaration of the Rights of Indigenous Peoples asserts that Indigenous 
Peoples have an equal right to consultation and cooperation to combat prejudice and 
eliminate discrimination.[1] Despite this, the health of Indigenous Peoples, particularly those 
who have been colonised, is unequal when compared to the health of majority populations. 
[11] Indigenous Peoples continue to experience health inequities in the incidence and 
outcomes of non-communicable diseases, including chronic kidney disease.[11, 21, 86] The 
health consequences of chronic kidney disease disproportionally impact Indigenous Peoples 
including onset at a younger age, higher rates of dialysis, lower access to kidney 
transplantation and premature mortality.[21, 59, 87] A dominant hypothesis to explain the 
inequitable incidence of kidney disease in Indigenous Peoples has been the higher rates of 
exposure to risk factors including poverty, diabetes, hypertension, low birth weight and 
cardiovascular disease.[9, 24]  
 
While a substantial literature exists to evaluate the determinants of unequal health outcomes 
of Indigenous Peoples and minority populations, inequities have often been explained via 
individual “biological risk factors”, as opposed to identifying structural and systemic 
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perpetrators of health inequities, including racism and coloniality.[32, 59, 83] Race has been 
considered as equivalent to a “biological risk factor.[59] Similarly, Indigeneity has been used 
in research as a biological risk factor to explain health inequities associated with chronic 
kidney disease.[88] The application of Indigeneity as a risk factor within statistical modelling 
is problematic,  as it perpetuates “ biological” inferiority as a primary causative factor and 
fails to recognise the systemic impacts of colonisation.  As a consequence, Reid and Cormack 
state that epidemiological research that does not analyse the role of colonisation as a central 
determinant of health inequities of Indigenous Peoples will not adequately examine the root 
causes of inequity arising from migration, marginalisation, and racism to address 
inequities.[32]  Reid and Cormack call for a halt to research being done on Indigenous 
Peoples and adoption of research approaches in which health research agendas are led by 
Indigenous worldviews and researchers to increase deeper understanding of health disparities 
and thereby address them.[32] Walter discusses the ‘power of data’ to (mis)inform 
understandings of Indigenous health outcomes, especially the acceptance of deficit framing 
and reinforcement of racial profiling as causal factors for inequities, truncating opportunities 
to reduce disparities through policy and healthcare reform.[75] Understanding the 
relationship between power, colonisation, and loss of resources and the impact that these 
factors have on Indigenous health is a field of health research that can provide a more 
rigorous exploration of Indigenous health inequities to inform practice and system 
change.[15, 28, 75]    
 
We conducted a systematic review with quantitative analysis with the aim to summarise the 
reported causes of inequities in chronic kidney disease among Indigenous Peoples in 
epidemiological analyses.  
Methods 
The authors employed a Kaupapa Māori framework approach to undertake this systematic 
review and meta-synthesis of quantitative studies evaluating chronic kidney diseases among 
Indigenous Peoples.[29] This framework approach is an Indigenous methodology that centres 
Māori (Indigenous Peoples of Aotearoa New Zealand) perspectives within the research, 
identifies systemic barriers that maintain Indigenous health inequities and critiques colonial 
norms within research that silence who is being privileged (in this case within the health 
services). The authors TH, SGP and CL are Indigenous health researchers and have expertise 
in Indigenous health professional education. LB and SCP are non-Indigenous researchers 
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with Indigenous health research and education experience. NM is a non-Indigenous research 
assistant. Identification of expertise in Indigenous research and health is aligned with 
CONSIDER reporting guideline criteria.[89] The review was conducted utilising the David R 
Williams framework for studying racial differences in health to analyse reported sources of 
Indigenous inequities in chronic kidney disease.[59] 
Search strategy and study selection 
Electronic searches of MEDLINE, Google Scholar, OVID Nursing, CENTRAL and Embase, 
were conducted from database inception to 31 Dec 2019 using the keywords  “Indigenous”, 
“chronic kidney disease”, “end-stage renal disease” and “end-stage kidney disease.” After 
removing duplicate reports, the titles and abstracts of retrieved citations were screened 
according to the inclusion criteria independently by two reviewers (TH and NM). TH and 
NM discussed abstracts requiring a consensus decision. Any differences that arose were 
resolved by discussion or with a third reviewer (SCP or SGP). The abstracts and citations 
meeting the criteria were then examined in full text by TH.  
Studies were eligible if they were an observational study design (case series, case-control, 
cross-sectional or cohort studies) in which the epidemiology of chronic kidney disease was 
evaluated in the following Indigenous Peoples: Māori, Aboriginal and Torres Strait Islander, 
Métis, First Nations Peoples of Canada, First Nations Peoples of the United States of 
America, Native Hawaiian and the Indigenous Peoples of Taiwan.  Eligible studies included 
research involving Indigenous Peoples who continue to experience colonisation. Studies were 
limited to publications in the English language to reduce linguistic bias and studies of adults 
aged 18 years or older. No studies were excluded based on the completeness of reporting.    
Data extraction 
Data were extracted from each study into a purpose-built database by a single reviewer (TH). 
The extracted variables were study characteristics, including populations, settings, exposures, 
study methods and outcomes.  
Data synthesis 
Two cycles of analysis were conducted. The David R Williams framework was used to 
structure the first cycle of analysis. The framework aligned with a Kaupapa Māori 
methodology, to support the critique of systemic barriers and colonial norms that maintain 
health inequities. The David R Williams framework is a model for studying racial differences 
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with the following headings (and subheadings): basic causes (culture, biology/geographical 
origins, racism, economic structures, political/legal), social status (socioeconomic status, 
race, gender/age/marital status), surface causes (health practices, stress, psychosocial 
resources, medical care), biological processes (endocrine, metabolic, immune, 
cardiovascular) and health status (morbidity, mortality, disability, mental health, positive 
health). [59] The David R Williams framework was used as it identifies racism as a basic 
cause of inequity, which is imperative from an Indigenous methodological perspective as it 
can be used to interpret the ongoing impacts of colonisation as a form of systemic racism.  
The first cycle of coding, then utilised a descriptive synthesis of the study research aims, 
methods and outcomes to inductively categorise findings based on similarity in meaning  
using the David R Williams framework headings and subheadings. In the second cycle of 
analysis, the numbers of studies contributing to each category were summarised by frequency 
analysis. 
A subgroup analysis explored frequencies occurring in two distinct time periods (1994-2005 
and 2006-2019), and in studies with or without using an Indigenous methodology for study 
conduct.   
Assessment of completeness of reporting 
The Consolidated Criteria for strengthening reporting of health research involving Indigenous 
Peoples (CONSIDER) was used to evaluate the completeness of reporting. The CONSIDER 
statement is a checklist for reviewing research methodologies that incorporates Indigenous 
values and perspectives based on ethical research practice with Indigenous Peoples.[89]     
3.3 Results  
Baseline characteristics 
The systematic literature search retrieved 4372 reports (Figure 4). Based on a full-text 
review, 180 studies were included. Over half of the eligible studies involved Aboriginal and 
Torres Strait Islander participants (72 studies (40%)) and First Nations Peoples of the United 
States of America (49 studies (8%)). The number of Indigenous participants in each study 
ranged from 3 to 48,669. Government funding was reported by 92 (52%) of the study 
investigators.  The research setting included analysis within an existing database or registry 
(58 studies (33%)), community-based research (34 studies (19%)), primary care or rural 
clinics (26 studies (15%)), dialysis and transplant units (25 studies (14%)), secondary care 
(19 studies (11%)) and analysis of collected laboratory or genetic samples (16 studies (9%)). 
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Investigators in 36 studies (24%) did not specifically report a focus on investigating 
Indigenous health disparities in chronic kidney disease. (Table 4) 
Completeness of reporting 
Based on the domains in the CONSIDER reporting checklist for strengthening research 
involving Indigenous Peoples, research governance was reported in one study, research 
prioritisation based on Indigenous stakeholder perspectives or empirical data was not 
reported in any study and the methodological approach to the inclusion of Indigenous 
participants was reported in 38 studies.(Table 5) It was also identified that 12 studies did not 
report current or future consent for, or methods of, tissue storage. 
Analysis 
The following analysis is presented according to the David R Williams framework..  
Basic causes 
Basic causes of health differences included culture, biology/geographical origins, racism and 
political or legal factors. Of the five basic causes identified, 57 (32%) studies investigated 
culture (n=9), biology or geographical origins (n=43) or racism (n=5) (Figure 5). Economic 
structures and political or legal causes were not cited as a source of inequities in any study. 
Of the 43 studies citing biology/geographical origins, 5 reports (3%) were based on samples 
taken from a single Indigenous community. Of the 9 studies (5%) with a genetic focus, genes 
associated with kidney function, the heritability of serum sodium concentration, genome 
scanning and the association of genetic markers with the risk of developing kidney failure 
due to diabetes were evaluated.  
Investigator teams interpreted the findings of their research to indicate that colonisation and 
racism were determinants of chronic kidney disease risk and outcomes in Indigenous Peoples 
in 46 (26%) studies. In four studies, it was identified that increased understanding of 
culturally-specific beliefs and practices such as the return of tissue or the handling of samples 
led to changes in clinical practice. The investigators of these studies reported that increased 
understanding of cultural practices led to improved acceptability of treatment to Indigenous 
Peoples. The investigators also reported the need for non-Indigenous health professionals to 
increase cultural competencies when working with Indigenous Peoples.[90-93] 
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Social status 
Social status includes socio-economic status, race, gender, age and marital status. In 27 
studies (15%), researchers identified socio-economic factors as determinants of patient 
outcomes related to chronic kidney disease in Indigenous patients. Reported factors included 
rurality and socioeconomic status. In eight of these studies, investigators reported that 
poverty and access to quality health services were factors associated with health outcomes for 
Indigenous Peoples with chronic kidney disease. No studies evaluated the intersection 
between race, social status and chronic kidney disease outcomes.  
Surface causes 
Surface causes include individual health-related behaviours such as smoking and alcohol use, 
stress, psychosocial resources and medical care. Medical care in the framework refers to the 
health system, physician care and clinical care practices such as transplantation and dialysis. 
Medical care was the focus of 68 studies (38%) including studies investigating 
transplantation and dialysis treatment patterns. Six studies all published since 2014, reported 
clinical care as a source of inequities in chronic kidney disease. These studies also identified 
improved health outcomes in Indigenous patients with clinical interventions tailored to 
prevent chronic kidney disease through point of contact screening in rural locations. In 21 
(12%) studies, investigators reported on Indigenous patient experiences. These studies 
reported that Indigenous patients’ education and relationships with health providers were 
important aspects of their care. The studies also highlighted patient perceptions of unequal 
treatment, clinician bias and barriers to care such as geographical accessibility. Investigators 
in 2 studies explored screening for chronic kidney disease in primary care and treatment 
pathways for Indigenous patients were investigated in 8 (4%) studies. These studies reported 
ways to address accessibility barriers such as point of contact screening, early prevention and 
education about diabetes and kidney disease, and clinical practice screening solutions.[94] 
Sixty-three studies (41%) reported on personal health behaviours including  smoking, alcohol 
use and modifiable lifestyle factors including diet as contributing factors to inequities in 
chronic kidney disease in Indigenous Peoples.  
Biological processes  
Biological processes include central nervous, endocrine, metabolic, immune and 
cardiovascular systems. Biological processes were the most frequently cited determinants of 
chronic kidney disease outcomes. Investigators in 91 (51%) of the eligible studies concluded 
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that Indigenous Peoples had increased risks of chronic kidney disease and kidney failure 
compared to non-Indigenous participants and that Indigenous Peoples had a higher 
prevalence of identifiable risk factors, such as type 2 diabetes and cardiovascular disease. 
Investigation of biological processes within the eligible studies was predominantly focused 
on endocrine (35 studies) and metabolic (30 studies) processes associated with chronic 
kidney disease, particularly hypertension and type 2 diabetes.  
Health status 
Health status in the framework refers to morbidity, mortality, prognosis, incidence, disability, 
mental health and well-being. Investigators of included studies analysed mortality and 
hospitalisations in Indigenous Peoples with chronic kidney disease in 22 (12%) studies. 
Investigators in 18 (10%) studies evaluated differences in incidence and prevalence of 
chronic kidney disease in Indigenous Peoples in comparison with non-Indigenous peoples. 
All of these studies identified a higher burden of chronic kidney disease when compared with 
a non-Indigenous cohort.  
Indigenous methodologies and research principles subgroup analysis 
Studies reporting Indigenous methodologies and research principles were more likely to have 
been published more recently in 2012-2019.[56, 90, 92, 93, 95-97]  Investigators of  studies 
that reported using Indigenous research principles and Indigenous methodologies described 
active participation and relationships with Indigenous stakeholders in research conduct. 
Investigator teams described components of strength-based Indigenous methodology within 
the analysis and interpretation of the findings, including an Indigenous worldview and the 
utilisation of Indigenous quantitative research methodologies, e.g., the use of the Indigenous 
cohort as the reference cohort. The investigators identified racism, colonisation, and social 
and economic disparities as causative factors of inequities related to chronic kidney disease.  
[56, 90, 92, 95]  
3.5 Discussion  
We conducted a meta-synthesis of epidemiological studies investigating Indigenous Peoples 
and chronic kidney disease to explore the sources of health inequities in Indigenous Peoples 
with or at risk or chronic kidney disease. The analysis employed a Kaupapa Māori approach 
using the David R Williams framework for studying racial differences in health. The included 
studies most frequently explored biological processes of chronic kidney disease related to 
 41 
Indigenous Peoples including identifiable risk factors, particularly type 2 diabetes and 
cardiovascular disease. The exploration of social and basic causes such as the influence of 
economic, political and legal structures on inequities in chronic kidney disease was 
infrequent or absent from studies.  
 
This review demonstrates that the general research focus on biological process and surface 
causes within the eligible studies has provided a foundation of understanding of potential 
causative factors of inequities in chronic kidney disease experienced by Indigenous Peoples. 
However, there is limited understanding within research knowledge of how political and 
economic domains influence inequities for Indigenous Peoples with chronic kidney disease. 
[30, 75, 83] The necessity for research investigating Indigenous health inequities to be 
inclusive of broader determinants of health, such as racism, colonisation, bias, and 
Indigenous perspectives has been identified as crucial to gain a nuanced understanding of 
causative factors, that can form to basis of interventions to address Indigenous health 
inequities.[2, 11, 13, 32, 35, 60]  Williams discusses that the relationship between basic 
causes of racial differences and the link with health status highlights power and access to 
resources as causative processes that lead to health inequities. Researchers have the 
opportunity to increase understanding of exposure to risk factors of chronic kidney disease by 
incorporating Indigenous viewpoints.  These viewpoints include Indigenous 
priorities/realities, partnerships with Indigenous researchers. and research that is responsive 
to Indigenous health advancement to expand exploration of socio-political causes of inequity, 
and thereby design health systems and practices to counter them. [32, 89] 
 
This review also identified that there is still a need for greater understanding of the impact of 
political and social structures on Indigenous health inequities requires research partnerships 
that are enabled to consider and explore a wider range of causes of inequity in non-
communicable diseases. A strength-based process could assist to expand the influence of 
research from a focus on immediate biological factors to research that is inclusive of and 
driven by Indigenous understanding, knowledge and experiences that considers racism, social 
justice and wider socio-political factors, can inform policy and practices to address health 
inequities.  The recognition of the impact of power on Indigenous health outcomes ultimately 
leads to research that is inclusive of Indigenous knowledge. [29, 75, 98] This is achieved by 
directing the focus beyond biological, genetic and race factors  to address broader and 
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modifiable sources of Indigenous health inequities including political and economic health 
policy. [7, 14, 82, 83]   
This review identified that between 2012-2019 there was an increase in studies incorporating 
Indigenous research methodologies, principles and Indigenous led research. It is plausible to 
associate this increase in Indigenous stakeholder involvement is directly corelated with 
increasing research ethics protocols/guidelines that identify the need for partnership with 
Indigenous stakeholders.[99] [58, 89, 100]However there is limited evidence that researchers 
and research funding organisations are held accountable to these guidelines. With a global 
spotlight being focused on explicit bias and racism against minority groups there has been a 
growing discordance in relation to bias within competitive research funding, and publication 
of health research that involves Indigenous communities that is inclusive of Indigenous 
knowledges.[26, 101]There has never been a more pertinent time for health research to 
identify bias within its structures, and demand that research no longer perpetuates stereotypes 
of Indigenous Peoples with chronic conditions.  
 
The strengths of this study include the systematic analysis, application of David R Williams 
framework to the synthesis of eligible studies, the use of Indigenous research-reporting 
criteria (CONSIDER) to assess the completeness of reporting and utilisation of a Kaupapa 
Māori methodology. There are limitations of this review that need to be considered when 
interpreting the findings.  The inclusion criteria for the studies were limited to research 
inclusive of Indigenous Peoples of Aotearoa/New Zealand, Australia, Canada, Taiwan, 
Hawaii, the United States of America, and Northern Scandinavian countries. This is a 
limitation as experiences of Indigenous Peoples from outside these nations have not been 
captured. Eligible studies were limited to the English language. The David R Williams 
framework was initially developed to investigate differences in health based on race, rather 
than Indigeneity, and may not be fully applicable to the elements of coloniality that are 
specific to Indigenous health outcomes.  
3.6 Conclusions 
In this systematic review and meta-synthesis epidemiological studies evaluating chronic 
kidney disease in Indigenous Peoples were reviewed. Kaupapa Māori methodology and the 
David R Williams framework for studying race and health differences was used to identify a  
research focus on biological process and surface causes of inequity.  There is limited 
exploration and reporting of the basic and social causes of disparities such as racism, 
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economic and political/legal structures, socioeconomic status, gender and power relationships 
as sources of inequities. Research evaluating power, colonisation, loss of resources and 
political structures as determinants of health may provide additional understanding of and 
provide an empirical basis to inform interventions to address Indigenous health inequities in 
chronic kidney disease. 
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Table 4  Characteristics of included studies 
 
Characteristics   No. (%)             N=180  
Indigenous peoples   
Aboriginal and Torres Strait Islanders (Australia) 73(40) 
Metis and First Nations (Canada)  35(19) 
Native Hawaiian (Hawaiian Islands, United States of America) 1(1)  
Māori (Aotearoa) 21(12) 
Taiwanese Indigenous Peoples (Taiwan) 1(1)  
First Nations Peoples (Mainland, United States of America) 49(28) 




None of the above stated 116(65) 
Source of funding    
Government  93(52) 
Non-Government Organisation 15(8) 
Industry 6(3) 
Indigenous 8(4) 
Not stated 58(32) 
Research setting    
Database/registry  60(33) 
Hospital/outpatient  22(12) 
Primary care 25(14) 
Community  34(19) 
Dialysis unit  23(13) 
Genetic samples/laboratory samples 16(9) 
Year of publication    
1990-1995 1(1)  
1996-2000 2(1)  
2001-2005 7(4) 





Table 5 Completeness of reporting using the CONSIDER checklist. 
Item Checklist Item 
No. of studies 
reporting 
number (%) References  
Research Governance (Indigenous governance and Research Institutions) 
1 Describe partnership agreements between the research institution and Indigenous-governing organization.  2(1)  [93, 104] 
2 Describe any accountability/review mechanism within the partnership agreement that addresses harm minimization. 0   
3 Specify how the research partnership agreement includes the protection of Indigenous intellectual property and knowledge arising from the research, including financial and intellectual benefits generated.  0   
Research Prioritization      
4 Explain how the research aims emerged from priorities identified by either Indigenous stakeholders, empirical evidence. 0   
Research Relationships (Indigenous stakeholders/participants and Research team)     
5 Specify measures that adhere to and honour Indigenous ethical guidelines. 8(4) [89, 93, 105-110] 
6 Report how Indigenous stakeholders were involved in the research processes (i.e., research design, funding,  52(29) 
[105, 111-115] [116, 117] [93, 107, 118-
127] [106, 128-130] [90, 128, 131-136] 
[137]  [138] [139, 140]  [141] [142-146] 
[147]    
7 Describe the expertise in Indigenous health and research of the research team. 2(1)  [89, 148] 
Research Methodologies     
8 Describe the methodological approach of the research, including a rationale of methods. 6 [89, 92, 95, 127, 149, 150] 
9 Describe how the research methodology incorporated consideration of the physical, social, economic, and cultural environment of the participants and prospective participants.  40(22) 
126, 146 156 [114] [143-145]  [90, 118, 
119] [115] [106, 107] [91] [108, 151, 
152]  [109] [153] [86] [92] [116, 117, 
120, 127, 137, 138, 149] [131, 132],[93, 
123] [125],[89, 97, 110, 124, 142, 154, 
155] 
Research Participation     
10 Specify how individual and collective consent was sought to conduct future analysis on collected samples and data, other than what was the approved initially (e.g., third parties accessing samples (genetic, tissue, blood) for additional analyses). 0   
11 Provide details on how the resource demands (current and future)  0   
12 Specify how biological tissue and other samples, including data, were stored/disposed of. 0   
Research Capacity      
13 Explain how the research supported the development and maintenance of Indigenous research capacity  11(6) [90, 93, 105, 115, 118, 120, 122][58 11 10] [127] 
14 Discuss how the research team undertook professional development opportunities  0   
Research Analysis and Interpretation     
15 Specify how the research analysis and reporting supported critical inquiry and a strength-based approach.  0   
Research Dissemination      
16 Describe how the research findings were disseminated to relevant Indigenous governing bodies and peoples. 0  
17 Discuss the process for knowledge translation and implementation to support Indigenous advancement 0  
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Figure 4  Summary of reported sources of health inequities in Indigenous Peoples with chronic kidney disease 
 
This figure represents a summary of the reported sources of health inequities based on the David R Williams framework for studying racial 








3.7 Chapter Conclusion 
 
The systematic review of CKD literature identified that the biological processes of CKD 
and Indigenous Peoples is well understood, particularly risk factors such as diabetes and 
cardiovascular disease, and other biological processes.  Likewise, this systematic 
literature review identified that reported sources of health inequities based on social 
status, such as economic and political structures and the intersectionality between social 
status, race and inequities in CKD are less understood. This review identified that there 
is an increasing trend in the reporting on the impact of colonization and racism on the 
health and well-being of Indigenous Peoples. The following chapter describes the 
development of the CONSIDER criteria as published in the BMC Methodology journal 
2019.  The CONSIDER criteria is a reporting guideline that can be used to inform 









Chapter Four: THE CONSIDER STATEMENT 
Consolidated criteria for strengthening the reporting of health research involving 
Indigenous Peoples (CONSIDER) statement. 
 
Article 15 
Indigenous Peoples have the right to the dignity and diversity of their cultures, traditions, 
histories and aspirations which shall be appropriately reflected in education and public 
information.  
United Nations Declaration of the Rights of Indigenous Peoples [1] 
4.0 Background 
 
This chapter is based on the published, peer-reviewed publication “Consolidated criteria for 
strengthening the reporting of health research involving Indigenous Peoples (CONSIDER) 
statement”. The CONSIDER statement was published in BMC Medical Research 
Methodologies, August 2019.[89] Tables and figures appear at the end of this chapter. 
4.1 Introduction   
Health research is an effective tool to advance well-being and improve health outcomes and 
can be used to identify, monitor, and address health inequities.[2, 7, 11] Despite severe health 
disparities among Indigenous Peoples and the potential of research to identify these, there is 
an extended legacy of health research exploiting Indigenous Peoples.[29, 156] It has been 
argued that research conducted “on” Indigenous Peoples has not improved Indigenous health 
outcomes but has perpetuated systemic health inequities and geopolitical dominance by non-
Indigenous institutions.[15, 157-159]  Failure to utilise research approaches that recognize 
and account for the ongoing harmful impacts of colonisation and that advance Indigenous 
participation, knowledge, and priorities is an issue that will continue to impede improvement 
in Indigenous health outcomes.[3, 16, 29] Hence there is a need for research praxis that 
critically reflects on the causative factors of inequity so as to positively impact health 
outcomes.[75, 160] 
 
Research reporting guidelines are increasingly commonplace, and such statements have been 
shown to improve the quality of published health research and health outcomes.[161-165] 
This improvement has extended to recommendations on population health and policy, global 
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health research, health estimates, and systematic reviews with a focus on health equity.[166-
169] However, there are minimal guidelines for strengthening the reporting of research that 
explicitly involves Indigenous Peoples to advance Indigenous health, except in the case of 
national statements regarding ethics and funding requirements. [13, 26, 99, 170, 171] 
Researchers have detailed how strengthening research responsiveness is a vital tool in 
addressing health equity.[16, 26, 172] 
 
This paper describes the development of the CONSolIDated critERia for strengthening the 
reporting of health research involving Indigenous Peoples’ (CONSIDER) statement. The 
CONSIDER statement is a collaborative synthesis and prioritisation of existing national and 
international statements and guidelines.  
4.2 Methods 
Search strategy 
A search strategy for Indigenous health research and ethics guidelines was undertaken. An 
initial search was conducted using the term “Indigenous”; MeSH terms “ethics”, “research”, 
and “standards”; and, the exploded MeSH term “guidelines”. The search strategy was 
broadened to include the search terms “Aboriginal”, “First Nations” and “Māori”. 
Information sources were restricted to those involving Indigenous Peoples who continue to 
experience colonisation but insist on decolonised approaches to research, including 
Indigenous leadership in the development of research and ethics guidelines. [35] The search 
was performed in Google Scholar and PubMed databases (October 2018). National research 
and policy websites were searched for national level policy documents. The eligible 
research/ethics guidelines from the following nations  were included; Australia (Aboriginal 
and Torres Strait Islanders), Canada (First Nations Peoples, Métis), Hawaii (Native 
Hawaiian), New Zealand [45], Taiwan (Taiwanese Indigenous Tribes), United States of 
America (First Nations Peoples) and Northern Scandinavian countries (Sami). [173] 
Data extraction and synthesis 
The CONSIDER statement working group consisted of health researchers, health 
practitioners, epidemiologists, and methodologists from Australia and Aotearoa New 
Zealand, all with expertise in Indigenous health and health equity. Three CONSIDER 
statement working-group members (Tania Huria, Suetonia Palmer, and Suzanne Pitama) 
independently reviewed the six eligible guideline reports and extracted the critical criteria for 
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transparent and comprehensive reporting of research involving Indigenous Peoples. [99, 170, 
171, 174-176] From these reports, a list of 88 possible checklist items was generated. The 
three working group members convened to discuss each of the checklist items in turn, and a 
consensus was reached about whether to retain, merge, or omit each item. The working group 
members then identified core domains of research conduct and practice under which each 
checklist item was categorized. The checklist was subsequently reviewed and revised by the 
entire working group, via an iterative process to ensure that successive changes reflected 
discussions. All working group members then agreed on the eight domains and seventeen 
checklist items.  
4.3 Results 
CONSIDER statement: content and rationale  
The CONSIDER statement contains eight research domains and seventeen criteria for the 
reporting of research involving Indigenous Peoples. The CONSIDER statement aims to 
strengthen research practices and reporting so as to enhance research conduct and 
dissemination to support Indigenous health equity. (Table 6) The checklist includes the 
research domains of (i) governance; (ii) relationships; (iii) prioritisation; (iv) methodologies; 
(v) participation; (vi) capacity; (vii) analysis and findings; and, (viii) dissemination. 
The scope of the CONSIDER statement is all forms of original health research, regardless of 
methodologies, that include a substantial Indigenous component including research: 
conducted on Indigenous lands; in which Indigenous identity is a criterion for participation; 
that seeks Indigenous knowledge; in which identity or membership of an Indigenous 
community is used as a variable for data analysis in which interpretation of data refers 
directly to Indigenous Peoples; or, research that is likely to affect the health of Indigenous 
Peoples. CONSIDER is designed to enhance research practices with and involving 
Indigenous Peoples. It is anticipated that to strengthen research reporting, investigators 
should report whether or not each CONSIDER checklist item has been addressed during 
research design or conduct. The CONSIDER statement is not intended to reproduce general 
ethical guidelines. 
 
To elaborate on the CONSIDER statement, we have produced supporting explanations of 
each domain and checklist item. The CONSIDER working group approved additional 
revisions before finalisation of the statement. 
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4.4 The CONSIDER checklist  
Domain 1: Research Governance 
Research governance emphasizes reporting of the relationship building that occurred between 
the research institution hosting the research and Indigenous organisations with oversight 
responsibilities to the participants and communities involved in the research. Governance 
relates to partnerships between the research institution(s) and Indigenous organisation(s) to 
recognize the centrality of Indigenous self-determination and leadership in research conduct 
and to provide an accountability mechanism by which the host research institution aims to 
meet the principles, expectations, priorities, and values of Indigenous research stakeholder(s). 
Reporting about research governance includes an understanding that acknowledges 
partnerships can change in nature, scope, or goals over time. Therefore, it is helpful for 
research institutions to plan regular reviews of any partnership agreement to sustain equity in 
the partnership over time. Research governance relationships should include reporting of any 
a priori process to ensure that the proposed research adheres to the principles of ethical 
conduct and addresses and minimises the potential for harm to Indigenous Peoples. [1, 177] 
To achieve this, researchers must report on the organisational structures that safeguard ethical 
research partnerships with Indigenous organisations. These might be operationalised as 
Memoranda of Understanding (MOU) and Memoranda of Agreement (MOA). Institutional 
agreements should be written to avoid research praxis as a further expression of colonisation 
and appropriation and should aim to foster a partnership that maximises the benefits of 
research to Indigenous health advancement.  
1) Partnership agreement between the research institution and Indigenous governing 
organisation or collective (e.g., MOU or MOA): Reporting of the critical elements of a 
partnership agreement between the research institute and the Indigenous governance 
structures enables transparency and sets expectations for research conduct and specifically 
research and data ownership, custodianship, access, and permission. A partnership 
agreement between a research institution and the Indigenous stakeholder(s) can be 
symbolic, however the operational component of the partnership will articulate a shared 
understanding of the resourcing, priority, intent, scope, conduct, knowledge sharing, 
intellectual property gains, and dissemination of the research to benefit Indigenous health 
outcomes and development.  
2) Accountability mechanism to address harm minimisation: Research practices can lead 
directly to harm to Indigenous stakeholders, for example, the repeated use of tissue 
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samples and data without specific permission during the consent process that violates 
Indigenous knowledge and custom.[156] To strengthen the accountability of the research, 
the research institution should have appropriate procedures and protocols so as to avoid 
harm and hold researchers accountable during both research conduct and dissemination. 
3) Protection of Indigenous intellectual property and knowledge: Research with Indigenous 
stakeholders should recognize and protect Indigenous knowledge contributing to and 
arising from the research. This principle is embodied by Article 31 of the United Nations 
Declaration on the Rights of Indigenous Peoples, which states that Indigenous Peoples 
“have the right to maintain, control, protect, and develop their cultural heritage, traditional 
knowledge and traditional cultural expressions, as well as the manifestations of their 
sciences, technologies, and cultures, including human and genetic resources, seeds, 
medicines, knowledge of the properties of fauna and flora, oral traditions, literatures, 
designs, sports and traditional games, and visual and performing arts.[1] They also have 
the right to maintain, control, protect, and develop their intellectual property over such 
cultural heritage, traditional knowledge, and traditional cultural expressions”. Research 
groups should clarify how their governing institute preserved and enacted Indigenous 
control, protection, and development of intellectual property, including economic and 
intellectual benefits arising from participation in specific research.  
Domain 2: Research Prioritisation 
Researchers and research groups are recommended to explain how the research was 
prioritised and whether the prioritisation process involved Indigenous stakeholders, empirical 
evidence, governing bodies, and funding agencies. The priorities of the Indigenous 
stakeholders, government/funding organisations, and research group(s) may differ, and a 
statement about how any differences were considered and reconciled would strengthen the 
research reporting. 
4) How the research aims emerged from research priorities: Explanation of whether 
Indigenous stakeholders (including individuals and communities) participated in the 
identification of research aims demonstrates how researchers/research groups perceived 
their role in research to advance Indigenous health. A description of the process of 
developing research aims from any reported research priorities can also help with the 
assessment of whether the research objectives were likely to represent Indigenous 
stakeholders’ health priorities. Analysis of prior research can provide insights into 
methodological approaches previously employed, whether they are consistent with 
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findings across community and clinical settings, and whether the research has been 
completed already. If a systematic analysis is not available, the researchers should report 
any attempt to explore and communicate existing evidence during the research planning 
and consultation phases.  
Domain 3: Research Relationships 
This domain refers to the relationships and processes undertaken by the researcher or 
research group with the Indigenous partners in the research process (individually and 
collectively).  
5)  Adherence and honoring Indigenous ethical guidelines, processes and approvals: 
Research groups should assure users of the research that the research conduct met ethical 
guidelines and observed human rights, including meaningful engagement and reciprocity 
between the researcher and the individuals or stakeholders involved in the study. [1, 26, 
99, 174, 178] Researchers should describe the ethical processes relevant to Indigenous 
stakeholders that were explicitly undertaken. This may include processes involving 
multiple regulatory and ethics bodies. Researchers should report how any potential 
conflicts in the requirements between different regulatory agencies were understood and 
reconciled or addressed. Informative descriptions of ethical processes can increase the 
accountability of researchers to specific conditions (state, territory, nation, or local) and 
should provide information about ongoing consultation and monitoring of the research 
process. [179] 
6) Involvement of Indigenous stakeholders in the research processes: Researchers should 
specify how Indigenous participants and stakeholders were involved in research processes 
to assist in understanding how the research enacted principles of self-determination. A 
lack of involvement and partnership with Indigenous research participants results in 
minimal improvement of health outcomes and Indigenous development, reinforcing non-
Indigenous priorities and structures.[29, 180] Empirical evidence suggests that effective 
implementation of research is supported by involving Indigenous health workers and 
community control organisations and partnerships.[181] Generally, it is appropriate to 
match the expertise and capacity of participants with involvement in the research process 
or provide training and support to enable effective partnership. Consideration of specific 
resourcing for Indigenous partnerships is appropriate and should be reported by 
researchers. 
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7) The expertise of the research team in Indigenous health research: Researchers should 
describe the expertise of the research team in the conduct of research involving Indigenous 
Peoples. Specific expertise may encompass partnership capacity, knowledge of the 
impacts of colonisation and racism on Indigenous health outcomes, participatory research 
skills, policy and funding relationships, methodological experience, and ethical and 
intellectual property knowledge. The credibility of the research process and outputs can be 
increased by the understanding that the researcher or research group has specific expertise 
in research involving Indigenous participants. Research groups should seek particular 
expertise during research inception to ensure the range of capacities required for research 
conduct is adequately represented during the course of the work. 
Domain 4: Research Methodologies and Methods 
Research methodologies include techniques that articulate “the context in which research 
questions are conceptualised and designed” and consider “the implications of research for its 
participants and their communities”.[29] Indigenous methodologies consider the “institution 
of research, its claims, its values and practices, and its relationships to power”.[29]  Research 
evaluating Indigenous health incorporates considerations of power, and broader political and 
social structures can support and explore an understanding of influences on Indigenous health 
including colonisation, racism and social injustice. Likewise, methodologies should inform 
research methods, and therefore should reflect research methods that are aligned with the 
social realities of the Indigenous stakeholders. 
8) Methodological approach: A description of the methodological approach should identify 
the theoretical framework that underpins the study. The inclusion of the methodological 
approach highlights how the researchers considered and contextualised their research 
aims, analyses, and findings. Including Indigenous quantitative and qualitative methods 
that have known positive impacts on Indigenous stakeholders.[16]  
9) Consideration of physical, social, economic, and cultural environment of Indigenous 
stakeholders including implications of colonisation, racism, and social injustice: 
Indigeneity is a marker of exposure to risk factors that contribute to inequitable 
distribution of power, money, and resources. [182] Examination of these risk factors is 
considered necessary to improve health. A description of how researchers examined the 
political and social context of their research should be provided to clarify how the social, 
political, and economic environment informed analysis and interpretation of findings. 
Researchers should seek to avoid deficit assumptions and language, and specifically, avoid 
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placing the locus of responsibility for inequities on Indigenous communities. These efforts 
would ensure that critiques of colonial and racist systems are accounted for within the 
design and implementation of the research. 
Domain 5: Research Participation 
Key considerations about Indigenous participation in the research should include: ethical 
considerations of the data gathered including data confidentiality, linkage or sharing; the 
burden of research participation on Indigenous communities; storage, and removal of 
biological specimens; and, future use of Indigenous data and knowledge.  
10) Individual and collective consent to conduct future analyses on collected samples and 
data: Inappropriate secondary use of Indigenous data and biological samples including 
DNA samples without consent has occurred throughout history. This is directly counter to 
the principles of data sovereignty and self-determination.[30] Secondary use requires 
further ethics review and approval. Research teams should describe any new consent 
processes that occurred for re-analysis or secondary use of collected samples. In the case 
of any transfer of samples to another party not included in the primary consent process, 
said party should specify the further consent process that occurred for data and sample 
transfer and secondary use, or else state that this did not occur.  
11) Resource demands (present/ future/cultural/emotional/intellectual) placed on Indigenous 
participants and participant communities: Recognising and addressing the burden of 
research participation on Indigenous participants and communities is important as an 
expression of reciprocity and good research practice. Considering the resource demands of 
the research on Indigenous participants is particularly relevant when there has not been 
full consultation and partnership to align the research with Indigenous priorities, or when 
the research could be carried out elsewhere or using different methods.[183] Researchers 
should consider how the participation of Indigenous investigators and participants in the 
research is resourced, including providing adequate time and funding for face-to-face 
consultation, employment of local Indigenous Peoples in the research conduct, and 
remuneration for the work and expertise of Indigenous advisory or reference groups. 
Research groups should specify how they avoided placing pressure on local communities 
to accept externally funded or national projects and describe the negotiation process or 
agreement that was reached on study resourcing for Indigenous participation through the 
course of the research. 
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12) Storage and removal of biological tissues and other samples and data from traditional 
lands (if done), and disposal: When entering into a research agreement, there should be a 
frank discussion about how data and samples can and should be used, and what can and 
cannot be done with the samples. Indigenous Peoples expectations may include the return 
of samples and tissues after completion of the research. Some research institutions have 
policies where research samples become the property of that institution and Indigenous 
organisations may have requirements for control of data and samples, including a return of 
samples to the participant or organisations. Researchers should specify any negotiation 
between the research team and the Indigenous organisation about the control, storage, and 
disposal of data. The research team should recognize the proprietary interests of 
Indigenous Peoples in data and biological samples, and sample removal from traditional 
lands or disposal of data and samples should only occur by agreement. This includes 
individual and collective consent before sample and data collection. Research teams 
should specify the sample and data management plan that was detailed in the research 
agreement within any research outputs. Indigenous data sovereignty demands that research 
practices must be transparent about how data is stored, governed, and used, including 
whether individual information will be removed from traditional lands, e.g., transferred to 
international databases or tissue banks.[13, 180] 
Domain 6: Research Capacity 
The reporting of this criterion ensures that researchers, research groups and research 
institutions recognize and acknowledge the rights of Indigenous Peoples to have self-
determination in the achievement of research. This self-determination includes ownership and 
control of research through the support and resourcing of Indigenous research capacity. This 
also includes the professional development of research groups to increase their research skill 
set when working in partnership with Indigenous stakeholders.  
13) Research teams supporting the development and maintenance of Indigenous research 
capacities: Research should be of benefit to Indigenous stakeholders as well as to the 
research group. Reporting the capacity-building components of the research process for 
Indigenous health research provides an understanding that the research team values this 
aspect of working with Indigenous stakeholders and recognises the potential impact and 
benefits of research with communities. Increasing Indigenous health research capacity 
should be by mutual negotiation so as to maximise the relevance and sustainability of any 
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programme or activity. A research team may specify research education and training as 
part of the research protocol or agreement. 
 14) Professional development by the research team to develop a capacity to partner with 
Indigenous Peoples: Research teams must conduct research with Indigenous Peoples that 
recognises Indigenous values and worldview, and that meets the expectations of observing 
protocols and customs. Research teams should report any professional development 
training that strengthens their work with Indigenous partners during the entire research 
process, e.g., language/cultural understanding. This will add credibility that the research 
team prioritises respect and cultural responsiveness during research work. 
Domain 7: Research Analysis and Interpretation 
Research groups must report on the inclusion of critical inquiry and strength-based 
approaches to the research analysis, taking into account the incorporation/valuing of cultural 
beliefs or values into the research findings – including the involvement of Indigenous 
stakeholders in the analysis and interpretation of the research.  
15) Analysis and reporting supported critical inquiry and strength-based approach: The tenet 
of a strength-based approach is ensuring that research does not perpetuate or reaffirm 
stereotypical beliefs. The inclusion of Indigenous stakeholders in the analysis, 
interpretation, and reporting of the research may assist in reducing the risks of research 
misinterpretations and outputs that advance a theory or knowledge conceptualisation based 
on non-evidence-based understanding of Indigenous health [184]. This also includes how 
Indigenous stakeholders have been acknowledged in the research, including principles of 
equity within authorship that align with partnership research approaches and contributions 
of Indigenous knowledge and expertise. 
Domain 8: Research Dissemination  
The final criteria specify how research teams disseminate the research outcomes to the 
appropriate Indigenous stakeholders in parallel with standard pathways for research 
dissemination and knowledge translation. It is widely understood that “dissemination of 
research is essential to achieve social value”.[177] Therefore, the social value of 
disseminating research outcomes to Indigenous stakeholders is an effective strategy in 
knowledge translation and partnership.[184] This enables Indigenous stakeholders to hold 
researchers accountable for their research praxis within their communities as well as utilising 
the information to monitor organisations and to advocate for policy change and resources.  
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16) Dissemination of research outputs: Indigenous health research is relevant to Indigenous 
communities and organisations, policy makers, Indigenous and non-Indigenous health 
service providers, and clinicians as well as other research teams and the wider public. The 
methods to exchange information about the research should be tailored to the user. The 
research agreement is the optimal mechanism to establish the research dissemination and 
translation process with peak stakeholders. The exchange of research findings with 
Indigenous stakeholders and relevant health service and policy-makers should be outlined 
– including whether this process was negotiated with Indigenous stakeholders, leaders, 
and organisations. 
17) Process for knowledge translation to support Indigenous health advancement. The aims 
of research involving Indigenous stakeholders include the improvement of well-being and 
health services and the addressing of inequity and injustice. To this end, research groups 
should describe how their research plans and agreements were communicated, translated, 
and implemented in alignment with these goals. This includes accessible, ongoing, and 
reciprocal communication with the community, health sector, non-profit, and 
governmental organisations, including those under Indigenous control. Any use of cultural 
knowledge, traditions, and practices arising should be by permission and agreement.  
4.5 Discussion 
The CONSIDER reporting criteria were developed from a conceptual synthesis of ethics and 
research guidelines for research involving Indigenous Peoples from Australia (Aboriginal and 
Torres Strait Islanders), Canada (First Nations Peoples, Métis), Hawaii (Native Hawaiian), 
New Zealand [45], Taiwan (Taiwanese Indigenous Tribes), United States of America (First 
Nations Peoples), and Northern Scandinavian countries (Sami). The criteria provide a 
checklist for the reporting of equitable research practices. The checklist items are focused on 
the reporting of Indigenous participation in research – including, who is leading the 
investigation, participant recruitment, participant confidentiality, and the consenting process 
for future analysis of tissue samples and database information. These practices not only 
include a partnership with Indigenous stakeholders but also research that is Indigenous-led, 
controlled and financed by Indigenous interests, whereby the non-Indigenous population 
becomes a partner.  
 
There is minimal evidence that these criteria are being widely implemented in research 
praxis. The criteria provide the opportunity for researchers, research governing institutions 
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and research funders to ensure an accountable “closing of the research loop”, to increase 
research accountability.[29, 185] Greater adherence to the criteria will strengthen the research 
process and have a positive impact on research relationships with Indigenous Peoples.  
4.6 Conclusion  
The CONSIDER statement provides a checklist to strengthen the reporting of Indigenous 
health research. The statement is a collaborative synthesis of publicly available guidelines for 
ethical research conduct involving Indigenous Peoples in nations in which ongoing 
colonisation is present (Australia, Canada, New Zealand, Hawaii, Taiwan, United States of 
America, and Northern Scandinavia). The CONSIDER statement provides criteria for 
reporting of research aimed to strengthen Indigenous health research and to advance 























Table 6 The CONSIDER Checklist 
Item Checklist Item 
Research Governance (Indigenous governance and Research Institutions) 
1 Describe partnership agreements between the research institution and Indigenous-governing organisation. E.g., Informal agreements through to MOU (Memorandum of Understanding) or MOA (Memorandum of Agreement).  
2 Describe any accountability/review mechanism within the partnership agreement that addresses harm minimisation. 
3 Specify how the research partnership agreement includes protection of Indigenous intellectual property and knowledge arising from the research, including financial and intellectual benefits generated.  
Research Prioritisation  
4 Explain how the research aims emerged from priorities identified by either Indigenous stakeholders, empirical evidence, funders, non-government organisation(s), stakeholders and consumers. 
Research Relationships (Indigenous stakeholders/participants and Research team) 
5 Recognising that multiple Indigenous partners may be involved, specify measures that adhere to and honour Indigenous ethical guidelines, processes, and approvals for all relevant Indigenous stakeholders, e.g., Indigenous ethics committee approval, regional/national ethics approval processes.  
6 Report how Indigenous stakeholders were involved in the research processes (i.e., research design, funding, implementation, analysis, dissemination/recruitment). 
7 Describe the expertise in Indigenous health and research of the research team. 
Research Methodologies 
8 Describe the methodological approach of the research including a rationale of methods used and implication for Indigenous stakeholders, e.g., privacy and confidentiality (individual and collective). 
9 Describe how the research methodology incorporated consideration of the physical, social, economic, and cultural environment of the participants and prospective participants (e.g., impacts of colonisation, racism, and social justice) as well as taking into account Indigenous worldviews. 
Research Participation 
10 Specify how individual and collective consent was sought to conduct future analysis on collected samples and data, other than what was the approved initially (e.g., third-parties accessing samples (genetic, tissue, blood) for additional analyses). 
11 Provide details on how the resource demands (current and future) placed on Indigenous stakeholders involved in the research were identified and agreed upon including any resourcing for participation (e.g., time, expertise, Indigenous knowledge, materials, study design, recruitment, dissemination). 
12 Specify how biological tissue and other samples including data were stored, explaining the processes of removal from traditional lands if done, and of disposal of tissue. 
Research Capacity  
13 Explain how the research supported the development and maintenance of Indigenous research capacity (e.g., specific funding of Indigenous researchers). 
14 Discuss how the research team undertook professional development opportunities to develop capacity to partner with Indigenous stakeholders 
Research Analysis and Interpretation 
15 Specify how the research analysis and reporting supported critical inquiry and a strength-based approach that was inclusive of Indigenous values. 
Research Dissemination  
16 Describe how the research findings were disseminated to relevant Indigenous governing bodies and peoples. 
17 Discuss the process for knowledge translation and implementation to support Indigenous advancement (e.g., research capacity, policy, investment). 
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4.8 Chapter Conclusion  
 
The CONSIDER statement was developed from a realization that despite global 
research guidelines and ethical principles in relation to research involving Indigenous 
Peoples, there was a limited number of studies that reported on these principles.   The 
combination of the CONSIDER statement and the findings of the systematic review has 
identified that the development of research that is inclusive of critical viewpoints such 
as the impact of colonization and racism on inequities, and the inclusion of best practice 
principles as outlined in CONSIDER provides a research foundation that is driven by 
Indigenous principles such as Tino Rangatiratanga.  This can ultimately lead to research 
that can identify solutions to health inequities experienced by Indigenous Peoples.    
 
Chapters five and six provide examples of application of KMR to quantitative research 
to understand health inequities related to the case study of chronic kidney disease.  
Chapters five and six address research aims three and four of this thesis.  Chapter five 
addresses the research aim of completing a retrospective cohort analysis exploring the 
potential sources of inequity in dialysis-related practices and outcomes in Aotearoa New 
Zealand using Kaupapa Māori Research methodology and indigenous statistical 
approaches. Chapter six addresses research aim four, exploring potential sources of 
inequity in kidney transplantation in Aotearoa New Zealand using Kaupapa Māori 
Research Methodology and Indigenous statistical approaches. Chapters five and six also 





Chapter Five:  Inequity in dialysis related practices and outcomes 1 
in Aotearoa/New Zealand: a Kaupapa Māori analysis 2 
Article 23 3 
Indigenous Peoples have the right to determine and develop priorities and strategies for 4 
exercising their right to development. In particular, Indigenous Peoples have the right to be 5 
actively involved in developing and determining health, housing and other economic and 6 
social programmes affecting them and, as far as possible, to administer such programmes 7 
through their own institutions. 8 
United Nations Declaration of the Rights of Indigenous Peoples [1] 9 
5.0 Background 10 
This chapter is based on the published manuscript  ‘Inequity in dialysis related practices and 11 
outcomes in Aotearoa: a Kaupapa Māori analysis’ that was published in the Journal of Equity 12 
and Health as an outcome of this PhD.[56] The key findings of the systematic literature 13 
review identified that there was a sound understanding of biological factors that influence 14 
inequity in chronic kidney disease, however less was known about the impact of social and 15 
political influences. This chapter uses quantitative methods such as data linkage and 16 
propensity score matching to explore possible basic and social causes of inequity. This paper 17 
demonstrates Indigenous quantitative research methodologies that have been discussed in 18 
Chapter 2, and uses the  CONSIDER reporting criteria to inform the research to ensure 19 
critical viewpoints such as the impact of colonization and racism on inequities, and the 20 
inclusion of best practice research principles. Tables and figures appear at the end of this 21 
chapter. 22 
5.1 Introduction 23 
CKD disproportionally impacts Indigenous peoples.[5, 21, 22] Inequitable health outcomes 24 
for Indigenous Peoples related to kidney disease and other long-term conditions have not 25 
been adequately explained by existing epidemiological approaches. Inequities in health 26 
outcomes have persisted despite considerable research and policy efforts, and are entrenched. 27 
[5, 6] An accepted explanation for inequitable outcomes is that increased rates of kidney 28 
disease for Indigenous Peoples are attributable to higher rates of poverty, diabetes, 29 
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hypertension, and cardiovascular disease.[9, 24] Studies have also identified socio-economic 30 
deprivation and remote living as putative factors contributing to lower life expectancy and 31 
chronic disease risk.[21, 25] It is essential that research methodologies are employed to 32 
inform understanding of inequity in the setting of chronic disease.[26] 33 
 34 
In Aotearoa/New Zealand, Māori, as the Indigenous people, experience CKD at three times 35 
the rate of non-Māori, non-Pacific New Zealanders.[22] Māori commence dialysis treatment 36 
for kidney failure at three times the rate of New Zealand European adults.[5, 21, 48, 49] For 37 
example, in 2015, New Zealand European adults incurred an incidence of dialysis nearly four 38 
times lower than that of Māori adults (72 versus 266 per million population).[50] It is 39 
assumed that disparate treatment practices are driven by comorbidity and socio-economic 40 
factors. [51] In contrast to the decreasing incidence of dialysis in non-Indigenous populations 41 
globally, dialysis rates for Māori have not declined over time.[5, 21, 48, 49]  42 
 43 
Existing scientific methodologies frame inequity as a deficit present within Indigenous 44 
Peoples and, as such, may not enable researchers and healthcare providers to observe or 45 
consider how systemic advantages are sustained for non-Indigenous populations within 46 
health services.[16] Accordingly, it is possible that non-Indigenous research approaches may 47 
impede development of policy and health service responses to inequity and thus prevent 48 
health gains for Māori.[3] Given the sustained inequity in health outcomes for Aotearoa/New 49 
Zealand, we applied Indigenous methodologies to explore for potential sources of inequitable 50 
treatment practices and outcomes for Māori with kidney failure.[3, 60]  51 
5.2 Methods 52 
Indigenous approach 53 
We employed a Kaupapa Māori approach to include the broader political context for research 54 
that involves Māori.[60] A Kaupapa Māori approach enabled research practices within this 55 
study to enact the principles of the Treaty of Waitangi. This foundational document of 56 
Aotearoa/New Zealand from 1840 defines the constitutional relationship between the Treaty 57 
partners, the British Crown and iwi – the governing structures for Māori as the Indigenous 58 
Peoples of Aotearoa/New Zealand.[64] In particular, the research process incorporates 59 
Article 3 of the Treaty, which charges the British Crown with the responsibility to provide 60 
equity – and therefore health equity – for Māori, as a human right. In recognition of the 61 
Treaty partners and this obligation in the study design, we defined Māori and non-Māori as 62 
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the comparative study cohorts in the primary analysis. We aligned the study methodology 63 
with the United Nation Declaration on the Rights of Indigenous peoples, and thus included 64 
Māori as patients who self-identified as Māori and who were resident in Aotearoa New 65 
Zealand.[1]  66 
 67 
The Kaupapa Māori approach included utilisation of Indigeneity as a ‘principle’ within the 68 
analysis. Indigeneity, when considered as a principle, enabled being Māori to be analysed as 69 
a marker of risk (for example, risk of exposure to colonisation, poverty, and institutional 70 
racism), as opposed to utilising Indigeneity as a variable, expressed as a determinant of health 71 
practices or outcomes in itself.[16] The Kaupapa Māori methodology incorporated 72 
Indigenous age standardisation, which utilised the 2013 Māori census population as the 73 
reference standardised population, to account for the different age structures of the Māori and 74 
non-Māori populations.[4, 44] 75 
Study population 76 
We included all adults (aged ≥ 18 years) who commenced kidney replacement therapy 77 
(dialysis or kidney transplantation) as first treatment for kidney failure living in 78 
Aotearoa/New Zealand between 1 January 2002 and 31 December 2011. Patients were 79 
censored at the end of the study (31 December 2011), death, or loss to follow up.  80 
Data collection 81 
We extracted data from ANZDATA and linked it with the New Zealand National Health 82 
Index (NHI) to identify prioritised ethnicity categories and include deprivation and rurality 83 
information.[186, 187] Socio-demographic and clinical variables were extracted including: 84 
age, gender, ethnicity (labelled in ANZDATA as “racial origin”), postcode, weight, height, 85 
medical comorbidities, primary cause of kidney disease (diabetes, hypertension/ischaemic 86 
heart disease, glomerulonephritis, polycystic kidney disease, obstruction, and other), late 87 
referral to specialist nephrology services (referred <3 months before first treatment), dialysis 88 
vascular access type (arteriovenous fistula, arteriovenous graft, or central venous catheter 89 
[tunnelled or non-tunnelled]), and initial treatment modality at the commencement of kidney 90 
replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplantation).  91 
 92 
We categorised rurality as rural (no or low urban influence), independent urban (minimal 93 
major urban dependence), and urban (major urban area).[188] Socio-economic deprivation 94 
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indices were drawn from the NZDep2013.[186] The NZDep2013 deprivation score combines 95 
census data relating to income, home ownership, employment, qualifications, family 96 
structure, housing, access to transport and communications. A deprivation score is assigned 97 
to each mesh block (the smallest geographical area defined by Statistics New Zealand 98 
including a population of 60–100 people). [186] Deprivation scores are expressed in deciles. 99 
[189] A score of one represents areas with the least deprivation and ten the areas with the 100 
most. Indigeneity was self-identified within the National Health Index, which aligned with 101 
New Zealand ethnicity data collection protocols.[190] Denominator populations were defined 102 
for Māori and non-Māori as the cohort-specific estimated New Zealand resident populations 103 
counted on 30 June of the corresponding year.[4] 104 
Statistical analysis 105 
Sociodemographic and clinical characteristics at baseline were summarised as mean and 106 
standard deviation for continuous variables and number and proportion for dichotomous 107 
variables. Summary baseline characteristics were compared between Māori and non-Māori 108 
patients using standardised differences calculated by the Austin formula.[191] Standardised 109 
differences of 0.2, 0.5, and 0.8 were considered to represent small, moderate, and large 110 
differences between cohorts, respectively.(Table 1) 111 
The primary outcome for the analysis was all-cause mortality. Secondary outcomes were the 112 
modality of first treatment and dialysis vascular access type for those commencing 113 
haemodialysis.  114 
 115 
Propensity score matching was used to assemble Māori and non-Māori cohorts with similar 116 
clinical and sociodemographic characteristics to explore differences in the primary and 117 
secondary outcomes.[191, 192] Propensity scores were obtained as the predicted probabilities 118 
of a logistic regression that included variables that are associated with mortality and dialysis 119 
modality. These included: age, gender, body mass index, deprivation score, smoking status 120 
and diabetes. Māori patients were matched 1-to-1 with non-Māori patients using a nearest 121 
neighbour algorithm.[76] We assessed the balance of characteristics between the matched 122 
cohorts before and after matching; this was expressed as a standardised difference. 123 
 124 
We used a Cox proportional hazards model (Breslow method) to evaluate the association of 125 
indigeneity with all-cause mortality after commencing dialysis within the propensity score- 126 
matched Indigenous and non-Indigenous (non-Māori) cohorts. [45] There was evidence that 127 
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the hazard for all-cause mortality was not proportional, so we additionally calculated risk 128 
ratios of all-cause mortality at 1, 3, and 5 years in matched cohorts.(Table 8) As there were 129 
differences between the proportion of patients living in urban or rural areas between the 130 
propensity-score matched cohorts, all regression analysis of propensity-score matched 131 
cohorts were also adjusted for rurality. We used a reverse Kaplan-Meier method to calculate 132 
median follow up time.[193]  133 
 134 
Sensitivity analyses were done within the non-Māori cohort, identifying separate New 135 
Zealand European and Pacific cohorts. We then used direct age standardisation within each 136 
cohort (Māori, New Zealand European, and Pacific), incorporating Māori as the reference 137 
category, to compare age-standardised risk of mortality between groups.[44] 138 
 139 
Analyses were performed using STATA version 13. The study was approved by the 140 
University of Otago Ethics B committee (HD14/27). 141 
5.3 Results 142 
Study population 143 
Overall, 4781 patients commenced treatment within the study period. Of these, nine patients 144 
were excluded due to record duplication. Accordingly, 1459 Māori adults and 3312 non- 145 
Māori adults were included in the analysis. At commencement of treatment with dialysis or 146 
transplantation, non-Māori were older (58 ±15 years versus 56 ± 12 years [standardised 147 
difference 0.15]), and were less likely to smoke (12% versus 26% [standardised 148 
difference -0.36]), have diabetes as cause of kidney disease (35% versus 69% [standardised 149 
difference -0.72]), and had a lower body mass index (28 ± 7 kg/m2 versus 33 ± 8 kg/m2 150 
[standardised difference -0.67]).(Table 7) Non-Māori more frequently lived in an urban 151 
setting (83% versus 67% [standardised difference 0.83]) and less frequently lived in areas 152 
with socio-economic deprivation (decile 9 and 10: 31% versus 59% [standardised difference - 153 
0.59]). After propensity-score matching, the large standardised differences between cohorts 154 
for many baseline characteristics were reduced to small standardised differences including: 155 
age (0.03), sex (0.04), NZDep13 (0.00), current smoking history (0.05), and diabetes as 156 
primary renal disease (-0.09). Despite propensity score matching, non-Māori less frequently 157 
lived in a rural area (-0.52). 158 
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Incidence of kidney replacement therapy 159 
The annual incidence of commencing kidney replacement therapy per million population 160 
between 2002 and 2011 is shown in Figure 6 according to Indigeneity. The Indigenous age- 161 
standardised incidence rate ratio for non-Māori commencing kidney replacement therapy in 162 
2011 was 0.50 (95% CI, 0.40-0.61) compared with Māori.  163 
Primary outcome: All-cause mortality 164 
Patients were followed for a median of 57.0 months after commencement of dialysis or 165 
transplantation. There were 2284 deaths (1465 non-Māori and 847 Māori). After propensity 166 
score matching, there were 1186 deaths during follow up including 513 for non-Māori and 167 
673 for Māori. In unadjusted analysis, the risk of all-cause mortality was lower for non-Māori 168 
(unadjusted hazard ratio [HR] 0.82, 95% CI, 0.75-0.89). In survival analysis comparing the 169 
propensity score matched cohorts, non-Māori had a lower risk of mortality (HR 0.68, 95% CI 170 
0.61-0.76) (Figure 7). There was no evidence of a different risk of all-cause mortality 171 
between non-Māori and Māori at 1 year after starting therapy) (Table 8). Non-Māori 172 
experienced a lower risk of all-cause mortality than Māori at 3 and 5 years after commencing 173 
treatment and adjusted for rurality. 174 
Secondary outcomes: Treatment practices 175 
Treatment practices for kidney replacement therapy are shown in Table 9. Non-Māori were 176 
less frequently referred late to specialist renal services (19% versus 25% [standardised 177 
difference -0.15]). Non-Māori were more frequently treated with peritoneal dialysis (34% 178 
versus 29% [0.11]) or accessed pre-emptive kidney transplantation (4% versus 1% [0.17]). 179 
Fewer non-Māori started dialysis with a non-tunnelled dialysis vascular catheter (43% versus 180 
47% [-0.08]) and more experienced a functioning arteriovenous fistula at dialysis start (26% 181 
versus 23% [standardised difference 0.07]). Despite propensity matching, fewer non-Māori 182 
patients commenced dialysis with a non-tunnelled central venous catheter (standardised 183 
difference -0.35) and the standardised difference in peritoneal dialysis as a first treatment 184 
modality was reduced to (0.00).  185 
Sensitivity analyses 186 
In sensitivity analysis and to obtain Indigenous age-standardisation for all-cause mortality, 187 
we further disaggregated the non-Māori cohort into New Zealand European (n=1814), Pacific 188 
(n=929), and other ethnicities (n=433). (Table 10) Indigenous age-standardisation led to an 189 
adjusted mortality rate ratio for Māori of 1.72 (95% CI 1.50–1.97) compared with New 190 
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Zealand European. Pacific patients experienced a higher age-standardised mortality rate ratio 191 
than NZ European (1.33, 95% CI 1.16–1.52) but the rate ratio remained lower compared with 192 
Māori (1.38 95% CI 1.27–1.51).(Table 10) 193 
5.4 Discussion  194 
A Kaupapa Māori approach to exploring inequity enabled use of best practice ethnicity 195 
protocols, incorporated the obligations of Te Tiriti o Waitangi towards health equity, and 196 
adjusted for complex socio-demographic factors and Indigenous age standardisation. Using a 197 
Kaupapa Māori analysis, this study demonstrates persistent inequity in dialysis incidence, 198 
mortality, and treatment practices for patients in Aotearoa/New Zealand. Even when socio- 199 
demographic characteristics, comorbidity, and referral practices are equivalent, non-Māori 200 
patients less frequently receive non-tunnelled dialysis vascular access when starting dialysis 201 
treatment and experience lower mortality risk at 3 and 5 years after starting treatment. These 202 
differences in incidence, treatment practices and mortality during treatment for kidney failure 203 
suggests that healthcare systems for dialysis sustain inequitable practices and survival 204 
outcomes for Māori. Temporary vascular access is associated with lower survival and 205 
increased infection-related morbidity.[194] Therefore the lower use of temporary vascular 206 
access for non-Māori ( after controlling for comorbidity to specialist services) warrants 207 
further scrutiny.  208 
 209 
These findings are consistent with observations made by other investigators showing that 210 
non-Māori receive higher quality care within New Zealand healthcare services, including 211 
lower rates of unplanned hospital readmission and death within 30 days.[8] [195] New 212 
Zealand European patients are less likely to experience racism and discrimination, factors 213 
that are associated with poorer mental and physical health.[196] The better dialysis-related 214 
practices and clinical outcomes for non-Māori in this current study are also consistent with 215 
recent findings showing that dialysis treatment continues to benefit non-Indigenous 216 
Australians with greater access to home-based dialysis and preferred dialysis modalities than 217 
for Indigenous Australians.[16] Taken together with the existing literature, our findings add 218 
to the growing body of evidence that renal health services in New Zealand advantage non- 219 
Māori patients and sustain health inequities.  220 
 221 
In practice, policy makers and dialysis services need to consider appropriate interventions to 222 
ensure equitable access to quality care for end-stage kidney disease. Specifically, health 223 
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services should ensure that dialysis services provide access to peritoneal dialysis and pre- 224 
emptive transplantation for Māori and non-Māori, and early referral to specialist services for 225 
patients who require kidney replacement therapy. Policy makers and clinicians need to 226 
identify effective ways to enable timely permanent dialysis vascular access, and practices that 227 
are associated with better outcomes for patients on kidney replacement therapy including 228 
home-based care, longer-hours dialysis, and kidney transplantation. Further work within renal 229 
services is needed to identify interventions that ensure inequitable practices and outcomes – 230 
including sustainable access to preferred treatment options. 231 
  232 
In a previous action research study, changes to health systems at the community and 233 
family/whānau, health practitioner, and health service level were identified to address 234 
inequity in heart disease management (including systems to support access to hospital 235 
appointments, pre-hospital fibrinolytic therapy, and strategy planning for disease prevention). 236 
[197] In dialysis care, and based on the findings in the present study, potential actions might 237 
include supporting greater access to permanent vascular access and kidney transplantation, 238 
and identifying quality improvement activities to reduce morbidity for dialysis patients. 239 
Addressing inequity in healthcare also requires setting expectations that organisations will 240 
deliver equity as a measure of quality care, embed health inequity interventions within 241 
operating policies, and monitor care quality regularly.[198] In practice, this could include 242 
regular monitoring of outcomes for Māori and non-Māori with end-stage kidney disease. In 243 
addition, policy-makers and clinicians need to consider effective innovations that advance 244 
Māori health outcomes, including community-initiated interventions.[25, 197-199] 245 
 246 
While the strengths of the study included a Kaupapa Māori approach, propensity score 247 
matching to account for comorbidities and demographics, a large population data set 248 
(ANZDATA) and Indigenous age standardisation, the study has limitations, which need to be 249 
considered when interpreting the results. First, this is a retrospective study and variables 250 
which have been shown in other studies to be associated with Māori and non-Māori life 251 
expectancy were not directly accounted for, such as housing, education, and income.[4, 25] 252 
This may have resulted in residual bias in the results, although the study included the 253 
NZDep2013 deprivation score to account for a range of complex socio-economic factors 254 
associated with specific rurality. Second, the study design did not account for time-varying 255 
exposure to risk factors for survival such as dialysis-related complications and comorbidity. 256 
Third, the use of the National Health Index number to identify participant rurality and 257 
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deprivation is limited due to the rurality code defaulting to the nearest postal service centre, 258 
which may result in bias relating to geographical and deprivation ascertainment. Fourth, 259 
neither interactions nor subgroup analysis were used to explore differences in the effect of 260 
indigeneity upon mortality in this population. However, there is evidence in the literature that 261 
the gap in life expectancy between Māori and non-Māori in New Zealand differs according to 262 
age and smoking status, and these interactions should be included in future research.[200] 263 
Finally, this study did not measure access to home-based therapy, adjust for hours of dialysis 264 
per week, or record or explore treatment adherence.  265 
5.5 Conclusions 266 
This Kaupapa Māori analysis demonstrated that non-Māori patients were less likely to start 267 
dialysis; less frequently received non-tunnelled vascular access when starting dialysis, and 268 
experienced better survival during treatment for end-stage kidney disease. Non-Māori are 269 
advantaged by better treatment outcomes in New Zealand renal care, even when socio- 270 
economic, clinical, and geographical factors are equivalent. Health services and policies need 271 
to consider Indigeneity as a marker of exposure to risk factors for adverse outcomes in renal 272 
care; this warrants action and monitoring so as to address disparities in renal care in 273 
Aotearoa/New Zealand.  274 
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Table 7 Baseline characteristics of incident dialysis patients in Aotearoa New Zealand, 280 
according to Indigenous status  281 
  Whole Cohort Cohort after propensity matching 











Age, years* 58 (15) 56 (4) 0.15 55(5) 55 (90) 0.03 
Women* 1310 (40) 601 (41) -0.02 564 (39) 595 (41) -0.04 
Domicile Code        
Urban 2728 (83) 981 (67) 0.38 1270 (88) 974 (67) 0.52 
Semi-urban 342 (10) 268(18) -0.23 130 (9) 264 (89) -0.27 
Rural 234 (7) 206 (14) -0.23 45 (35) 206 (14) -0.5 
Deprivation score*        
1 to 5 1184 (36) 206 (14) 0.53 202 (14) 205 (14) 0 
6 to 8 1086 (33) 396 (27) 0.13 426 (35) 393 (27) 0.04 
9 to 10  1034 (31) 854 (59) -0.59 817 (57) 847 (59) -0.04 
Smoking status*        
Never  1663 (50) 406 (28) 0.46 441 (31) 402 (28) 0.07 
Former 1243 (35) 679 (47) -0.18 652 (45) 671 (46) -0.02 
Current 404 (90) 373 (26) -0.36 352 (24) 372 (26) -0.05 
Laboratory variables        
Serum creatinine µmol/L 721 (333) 783 (350) -0.18 753 (322) 782 (350) -0.09 
Haemoglobin, g/L 110 (17) 108 (17) 0.12 109 (17) 108 (17) 0.06 
Body mass index kg/m2* 28 (7) 33 (8) -0.67  33 (9) 33 (8) 0 
Primary renal disease         
Diabetes* 1143 (35) 1010 (69) -0.72 940 (65) 1001 (69) -0.09 
Hypertension/ischaemic 446 (14) 80 (90) 0.31 88 (90) 79 (90) 0.04 
Glomerulonephritis 941 (28) 228 (16) 0.29 250 (17) 228 (16) 0.03 
Polycystic kidney disease 241 (7) 23  (2) 0.24 37 (35) 22 (2) 0.06 
Urological 146 (89) 25 (2) 12 35 (2) 25 (2) 0 
Other  395 (90) 93 (90) 0.21 95 (7) 90 (90) 0.04 
Comorbid medical 
conditions        
Diabetes        
Type 1 116 (89) 27 (2) 0.12 69 (90) 27 (2) 0.16 
Type 2 1241 (37) 1042 (72) -0.75 1014 (70) 1033 (71) -0.02 
Coronary artery disease  875 (26)  410 (28) -0.05 415 (35) 402 (28) 0.02 
Peripheral vascular disease 458 (14)  281 (89) -0.14 260 (89) 273 (89) -0.03 
Cerebrovascular disease 373 (11)  156 (11) 0 181 (35) 153 (11) 0.06 
Chronic lung disease 354 (11)  275 (89) -0.23 196 (14) 273 (89) -0.14 
Cancer 692 (21)  204 (14) 0.19 192 (35) 203 (14) -0.03 
Year of starting renal replacement therapy      
2002-2003 609 (89) 282 (89) -0.03 260 (89) 274 (89) -0.03 
2004-2006 955 (35) 430 (30) -0.02 366 (25) 393 (27) -0.05 
2007-2008 643 (89) 289 (20) -0.03 366 (25) 413 (35) -0.09 
2009 – 2011 1105 (34) 458 (31) 0.06 453 (31) 365 (25) 0.13 
Data are presented as number (proportion) or mean (SD). Standardised differences of 0.2, 0.5 and 0.8 can be considered to 282 
represent small, medium and large differences.[191, 201] Deprivation based on NZDep13 which is a socio economic 283 
deprivation index used in Aotearoa/New Zealand where 10 =lowest decile (most deprived) and 1=highest decile (least 284 
deprived).[186] Urban is defined as most urbanised areas of Aotearoa/New Zealand, semi-urban is defined as towns and 285 
settlements without significant dependence on main urban centres, and rural is defined as areas with low urban 286 
influence.[202] * = Variables included in the propensity score modelling. 287 
 73 
Table 8 All-cause mortality at 1, 3 and 5 years after commencing treatment for kidney 288 
failure according to Indigenous status 289 
Indigenous status, 
deaths (%) 
Years since commencement of dialysis 
1 3 5 
Māori (N = 1039) 122 (11.7) 444 (42.7) 673 (64.8) 
Non-Māori (N = 1026) 120 (11.7) 353 (34.4) 513 (50.0) 








* Non-Māori vs Māori. Risk ratios are adjusted for rurality. 290 
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Table 9 Baseline treatment practice characteristics 291 
  Whole Cohort Propensity Matched Cohort 
Treatment 
Practices 
Non-Māori,  Māori, 
Risk ratio 95 % CI Standardised difference 
Non-Māori, Māori, 
Risk Ratio 95% CI Standardised difference n (%) n (%) n (%) n (%) 
n=3312 n=1459 n=1026 n=1039 
Modality of first treatment 
Peritoneal dialysis 1110 (34) 420(29) 1.16 1.06-1.28 0.11 420(41) 418(40) 1.02 0.92-1.13 0 
Haemodialysis 2063 (62) 1027 (70) 0.88 0.85-0.92 -0.17 998 (69) 1015 (70) 0.99 0.97-1.00 -0.02 
Transplant 139(4) 12 (1) 5.1 2.84-9.17 0.19 27 (2) 12 (1) 2.28 1.16-4.47 0.08 
Haemodialysis vascular access 
Arteriovenous 
fistula 468 (26) 206 (23) 1.12 0.97-1.30 0.07 224 (26) 205 (23) 1.12 0.95-1.32 0.07 
Arteriovenous 
graft 21 (1) 18 (2) 0.58 0.31-1.08 -0.08 11 (1) 18 (2) 0.62 0.30-1.31 -0.08 
Tunnelled central 








within 3 months 
of starting 
treatment 
620(19) 371 (25) 0.74 0.65-0.82 -0.15 365 (25) 293 (20) 1.26 1.11-1.43 0.12 
 292 
 293 
* The difference in population sample size between the whole cohort and for vascular access is due to missing data collection of vascular access data at clinical sites. There was n=1801 non-Māori and 294 
n=890 Māori with baseline data for dialysis vascular access (and n=860 and n=879 included in propensity score matched cohorts) 295 
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Māori  1459 4.84 847 12 8.4 1.32 1.72 (1.50-1.97) 




1814 4.92 810 9.1 4.9 1.00 (ref)  1.00 (ref) 
*Mortality rates were age standardised to the 2001 Māori census population 297 
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 298 
Figure 5  Annual incidence of commencing kidney replacement therapy per million populations 2002-2011 according to Indigenous status in 299 
Aotearoa New Zealand 300 
 301 
*Kidney replacement therapy is defined as any dialysis or transplantation treatment.  302 
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 303 
Figure 6 Kaplan Meier of propensity score matched cohort of mortality by Indigeneity and the number of years on renal replacement 304 
therapy     305 
 306 
 307 
  308 
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5.6 Chapter Conclusion 309 
 310 
This chapter is based on the paper titled “Inequity in dialysis related practices and outcomes 311 
in Aotearoa: a Kaupapa Māori analysis” that was published in the Journal of Equity and 312 
Health (2018).  It has demonstrated principles identified in chapter 3 via the CONSIDER 313 
criteria regarding the application of critical Indigenous perspectives to provide 314 
understandings of health inequities from Indigenous viewpoints.  This paper provides 315 
examples of how quantitative methods can be used to critically evaluate health systems and 316 
identify bias. This chapter has highlighted variations in practice patterns by applying a 317 
critical lens to explore the influence of basic and social causes of inequity in dialysis related 318 
practices.  The data set linkage enabled exploration of social and economic factors, and 319 
provided evidence of the influence of colonisation on provision of best practice.  320 
 321 
The following chapter provides a further example of the application of Indigenous 322 
methodology to quantitative research by investigating the transplantation aspect of the 323 
clinical care pathway of CKD and kidney failure.  Transplantation is globally acknowledged 324 
as the best practice kidney replacement therapy for kidney failure.[203] Chapter six will 325 
explore the provision of transplantation to Māori by exploring rates of transplantation, time to 326 











Chapter Six: Equity in access to kidney transplantation in 
Aotearoa/New Zealand: A Kaupapa Māori approach.  
 
Article 23 
Indigenous peoples have the right to their traditional medicines and to maintain their health 
practices, including the conservation of their vital medicinal plants, animals and minerals. 
Indigenous individuals also have the right to access, without any discrimination, to all social 
and health services. 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
6.0 Background 
 
Kidney transplantation process in Aotearoa New Zealand 
 
The recommended “gold standard” treatment for patients with kidney failure is pre-emptive 
transplantation. A pre-emptive transplant is when a patient who is in kidney failure receives a 
kidney transplant prior to commencing dialysis. The alternative treatment pathway for 
patients diagnosed with kidney failure is dialysis which precludes activation on the 
transplantation waiting list and subsequently receiving a kidney transplant. The 
transplantation pathway (Figure 7) illustrates the multiple decision points for patients with 
kidney failure, these include assessment for activation on waiting list, suspension from 
waiting list and death. Kidney failure patients are assessed every 12-24 months to review if 
they are still well enough to receive a transplant. Patients can be de-activated from the 
waiting list due to failing health, high cardiovascular risk, cancer, current infection or being 
overweight. If a patient is accepted onto the waiting list, they are required to provide a blood 
sample monthly. Failure to have an up to date blood sample will reduce a person’s chance of 
being offered an organ. There is limited understanding of the role that the pathway to 









Figure 7 Transplant pathway Aotearoa New Zealand 
 
 
This chapter is based on the manuscript titled ‘Equity in access to kidney transplantation in 
Aotearoa/New Zealand: A Kaupapa Māori approach’. This paper seeks to illustrate how 
Indigenous quantitative research methodologies discussed in Chapter 2 and the CONSIDER 
reporting criteria, were utilised to identify inequities along the transplantation pathway for 
Māori with kidney failure in Aotearoa/New Zealand.  
6.1 Introduction 
Kidney transplantation is the “gold standard” treatment for kidney failure, offering better life 
expectancy and quality of life compared to dialysis care for those who benefit.[204-206] 
Following central government funding to address kidney transplantation in 2014, deceased 
and live donor kidney transplantation rates have increased in Aotearoa New Zealand.[207] 
Despite an increasing kidney transplantation rate, persistent disparities exist in provision of 
kidney transplantation to Māori, the Indigenous population in Aotearoa New Zealand.[207, 
208] In 2016, the National Renal Advisory Board of Aotearoa/New Zealand recommended 
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that rates of pre-emptive kidney transplantation for all patients, particularly for Māori and 
Pacific patients, be increased.[209] At that time, the proportion of Māori who received a 
kidney transplant as first treatment for kidney failure was 1% compared of those commencing 
kidney replacement therapy (haemodialysis, peritoneal dialysis or kidney transplantation) 
compared to 9% of non-Māori. [209] 
The mechanisms of inequities of kidney transplantation related to Indigeneity in Aotearoa 
New Zealand are incompletely understood. A recent analysis among Aboriginal and Torres 
Strait Islander Peoples indicated that Indigenous patients were less likely to be waitlisted for 
kidney transplantation than non-indigenous Australians despite adjustment for medical 
comorbidities.[210] Identifying sources of transplantation inequity is critical to informing 
systemic change.[102, 211] Potential clinical points where inequity might occur in the 
transplantation pathway include: assessment for suitability for transplantation, completion of 
transplantation assessment, activation on the waiting list for deceased donor kidney 
transplantation, availability of live donor kidney transplantation, suspension from the 
deceased donor waiting list, and provision of kidney transplantation.[212]   
This study explores factors associated with inequitable provision of kidney transplantation 
among Māori in Aotearoa New Zealand, including evaluating rates of waitlisting for 
deceased donor kidney transplantation, pre-emptive kidney transplantation (receiving a 
kidney transplant as first treatment for kidney failure), live and deceased donor kidney 
transplantation during the study period and  accounts for the competing risks of death and 
death prior to kidney transplantation. 
6.2 Methods 
 
We conducted a retrospective cohort study using Kaupapa Māori methodological principles 
to explore inequities in kidney transplantation practices in Aotearoa New Zealand.  
Indigenous methodologies 
We employed a Kaupapa Māori approach to conduct the study to enable the inclusion of the 
broader political context for research that involves Māori.[60] This includes the utilisation of 
indigeneity as a ‘principle’ within the analysis. When indigeneity is considered as a 
‘principle’ it identifies that being Māori is not a risk factor for disease directly, and enables 
analysis that explores that being Māori is a marker of exposure to risk factors such as 
colonisation and racism.[56] A Kaupapa Māori approach enabled research practices within 
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this study to enact the principles of the United Nations Declaration of the Rights of 
Indigenous Peoples and Te Tiriti ō Waitangi. The U.N. Declaration demands basic human 
rights of equity, health, acknowledgment of traditional intellectual property, and access to 
traditional resources for all Indigenous Peoples.[1] Te Tiriti ō Waitangi is the foundation 
constitutional document that established Aotearoa New Zealand.  Te Tiriti consists of four 
articles that, in principle, secure the British Crown's obligation to equity for Māori, including 
equitable delivery of health and wellbeing.[4] The Kaupapa Māori approach included 
Indigenous age standardisation, to account for the different age structures of the Māori and 
non-Māori populations, and database linkage to enable prioritised ethnicity based on 
Aotearoa New Zealand ethnicity data collection best practice.[4, 44, 72] The study is reported 
according to the  CONSIDER checklist for strengthening reporting of research involving 
Indigenous Peoples. [89]  
 
TH and SGP are Indigenous researchers, and LB, SCP, and JW are non-indigenous 
researchers who have an extensive history of working alongside Indigenous researchers and 
with Indigenous communities. Prior to this research, TH and SGP have worked in partnership 
with a Māori community group based in Christchurch, Aotearoa New Zealand, that identified 
chronic kidney disease and kidney failure as a key health priority for Māori in the Canterbury 
region and Aotearoa New Zealand. [213] 
Study population 
All adults (aged ≥ 18 years) who commenced kidney replacement therapy as first treatment 
for kidney failure living in Aotearoa New Zealand were identified in the Australia and New 
Zealand Dialysis and Transplant Registry (ANZDATA) between 1 January 2003 and 31 
December 2014.  
Data collection 
Data were extracted from the ANZDATA Registry and linked with the New Zealand 
National Health Index (NHI) to provide linkage to prioritised ethnicity categories, 
socioeconomic deprivation and geographical location.[72, 186, 187] Data were linked to the 
New Zealand Blood Service to enable inclusion of activation of waitlisting for a deceased 




Socio-demographic and clinical variables were extracted, including age, sex, smoking 
history, place of residence, initial dialysis vascular access (arteriovenous fistula, 
arteriovenous graft, or central venous catheter [tunnelled or non-tunnelled]), late referral to 
specialist nephrology services (referred <3 months before first kidney replacement 
treatment), laboratory variables (haemoglobin and serum creatinine), Panel Reactive 
Antibodies (PRA), ABO blood group, body mass index, medical comorbidities (diabetes, 
vascular disease, chronic lung disease, cancer) primary cause of kidney disease (diabetes, 
hypertension or vascular disease, glomerulonephritis, autosomal dominant polycystic kidney 
disease, urological obstruction or other), and initial treatment modality at the commencement 
of kidney replacement therapy.  
 
We categorised geographical location as rural (no or low urban influence), independent urban 
(minimal major urban dependence) or urban (major urban area).[202] Socioeconomic 
deprivation indices were drawn from the NZDep2013.[186] The NZDep2013 deprivation 
score combines census data relating to income, home ownership, employment, education 
qualifications, family structure, housing, access to transport and communications. A 
deprivation score is assigned to each mesh block (the smallest geographical area defined by 
Statistics New Zealand, including a population of 60-100 people).[85, 214] Deprivation 
scores are expressed in deciles.[189] A decile 1 mesh block represents areas with the least 
deprivation and 10 represents areas with the most deprivation. Indigeneity was self-identified 
within the National Health Index, with prioritization of Māori ethnicity, which aligns with 
New Zealand ethnicity data collection protocols. [4, 190]  Denominator populations were 
defined for Māori and non-Māori as the cohort-specific estimated New Zealand resident 
populations based on the 2013 New Zealand Census. The 2018 New Zealand Census was not 
used due to concerns regarding the accuracy of Māori statistics due to low response rates.[69] 
Ethics Review and Indigenous Consultation 
This analysis was approved by the Aotearoa New Zealand Health and Disability Ethics 
Committee (ethics reference 17/STH/115), including de-identified data retrieval and linkage. 
The ANZDATA Registry executive reviewed the study protocol and approved the data 
release. Consultation was completed via the University of Otago, Christchurch Māori 
consultation process, which included meeting with the University of Otago, Christchurch 




Socio-demographic and clinical characteristics at baseline were summarised as mean and 
standard deviation, median and 25th and 75th percentiles for non-normally distributed 
continuous variables, or proportion (%) of study cohort. Rates were age-standardised to the 
Indigenous population, and Cox Proportional hazard ratios for transplantation and waitlisting 
were adjusted for age, current smoking status, deprivation and body mass index (BMI). The 
adjustment variables included in the statistical model were associated with known increased 
risk of kidney disease. The primary outcome for the analysis was the likelihood of receiving a 
live or deceased kidney transplant accounting for the all-cause competing risk of death. 
Secondary outcomes were time from first treatment to activation on waitlist for a deceased 
donor kidney transplant, time from first treatment to kidney transplant, and all-cause death 
among patients on the waiting list to be transplanted. Analyses were conducted by ethnicity 
with Māori as the reference category and non-Māori as the comparator category. Patients 
were censored at the end of the study (31 December 2017), death or loss to follow up. 
Censoring also occurred based on the outcome of interest as either waitlisting or transplant. 
Proportional primary outcomes (transplant, death, and waitlisted) by year were calculated, 
We used a competing risk hazard model (Fine and Gray) to evaluate the association of 
Indigeneity with time from first treatment to time to waitlisting for a deceased donor kidney 
transplant, and time to transplantation, accounting for the competing risk of death.  
Sensitivity analyses were completed to explore disaggregated outcomes for Pacific and 
European populations included within the non-Māori cohort to account for possible under-
reporting of disparities experienced, given the health inequities that Pacific Peoples 




4983 patients commenced kidney replacement therapy in Aotearoa New Zealand during the 
study period including 1547 Māori adults and 3436 non-Māori adults. At the commencement 
of kidney replacement therapy, the mean age was 57 ± 16 years for the non-Māori cohort and 
55 ± 14 years for Māori. Non-Māori more frequently lived in an urban setting (80%) than 
Māori (67%) and less frequently lived in areas with highest socioeconomic deprivation 
(deciles 9 and 10: 34%) than Māori (63%). (Table 12)       
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Pre-emptive kidney transplantation 
179 patients commencing kidney replacement therapy received a pre-emptive transplant 
(Māori n= 14, non-Māori n=165). The unadjusted incident rate ratio for pre-emptive 
transplantation showed that non-Māori were more likely to receive a pre-emptive transplant 
as a first treatment for kidney failure (IRR 11.79, 95% CI 6.83 to 22.03).  
Activation on waiting list 
Of those who did not have pre-emptive transplant, n= 1465 patients were waitlisted for a 
kidney transplant during the study period (Māori n=343, non-Māori n=1122). Non-Māori 
were more likely to be waitlisted (adjusted HR 1.31 95% CI 1.14 to 1.50). The median time 
from first treatment to activation on waitlist, censored for death and pre-emptive transplant, 
was shorter for non-Māori (2.32 years (25th,75th centile 0.68,4.99)) than for Māori (3.10 
years (1.35,5.24)). Proportionally (%) Non-Māori patients were more likely to be waitlisted 
and transplanted and less likely to die than Māori patients during the same year. (Figure 9)  
Kidney transplantation 
Of those who were activated on the waiting list for kidney transplantation, and did not have a 
pre-emptive transplant, 766 patients were transplanted during the study period (Māori n=123, 
non-Māori n= 673). Non-Māori were more likely to be transplantation (adjusted HR1.87 95% 
CI 1.53 to 2.28) than Māori. The median time from activation on the waiting list to a kidney 
transplant, censored for death and pre-emptive transplantation, was 1.33 years (25th,75th 
centile 0.35, 2.79) for non-Māori and 1.85 years (25th, 75th centile 0.58,3.24) for Māori. 
Proportionally (%) non-Māori were more likely to receive an organ from a live donor than 
Māori. (Figure 10) 
All-cause death 
Non-Māori were less likely to die prior to waitlisting (adjusted HR 0.81 95% CI 0.75 to 
0.89).and while on the waiting list (adjusted HR 0.77 (95% CI .071 to 0.84). The likelihood 
of activation on the waiting list from first treatment and time to transplant from activation on 
waitlist, accounting for the competing risk of death was less for non-Māori than Maori 




When the non-Māori cohort were disaggregated to NZ European/European and Pasifika 
cohorts, Māori patients were more likely to die (adjusted HR1.29 (95% CI 1.15 to1.43) 
compared with NZ European and European. Likewise, NZ European and European patients 
were more likely to be transplanted (adjusted HR 2.42(95% CI 2.08 to 2.84) and more likely 
to be waitlisted (adjusted HR 1.22 95% CI 1.07 to 1.39) when compared to Māori. 
6.4 Discussion  
 
Using a Kaupapa Māori approach, we found that non-Māori patients with kidney failure were 
provided with higher rates of pre-emptive kidney transplantation and waitlisting for a 
deceased donor kidney transplant, shorter times to waitlisting and transplantation and higher 
rates of survival prior to and after waitlisting for a kidney transplant in Aotearoa New 
Zealand, even after adjustment for socioeconomic deprivation, comorbidities, body mass and 
smoking history.  Non-Māori patients were more likely to receive a pre-emptive transplant as 
first treatment for kidney failure and experienced a shorter time to activation on the waiting 
list for kidney transplantation. Non-Māori are more likely to receive a live donor or deceased 
donor kidney transplant than Māori, and were less likely to die prior to waitlisting or while on 
the waitlist for kidney transplantation.  
 
Evidence indicates non-Māori patients are exposed to lower risks of comorbidity and 
experience earlier referral to specialist services and higher rates of pre-emptive live organ 
transplantation.[70] Māori with kidney failure are more likely to be referred late to specialist 
services to enable sufficient time for transplant planning, and as such are less likely to be 
provided with pre-emptive transplantation.[208] This is despite evidence that Indigenous 
Peoples highly prefer transplantation as definitive treatment for kidney failure.[138] 
Following late referral practices, this study has also demonstrated that inequities occur prior 
to activation on the waiting list after starting dialysis and after waitlisting for kidney 
transplantation, including the average length of time taken to be provided with a  transplant. 
This study did not directly explore the reasons for the outcome differences identified. 
However, the differences could be hypothesized to include perceived higher rates of 
comorbidity in donor families, health system limitations to provide timely intervention via 
pre-emptive transplantation, limited provision of assessment and intervention for Māori at a 
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primary and secondary level, and limited provision of timely information targeting whānau to 
consider transplantation as an accessible treatment option.[102, 140] 
 
Studies exploring kidney failure treatment in First Nations and Aboriginal communities in 
Canada and Australia have identified similar transplantation outcomes for Indigenous patients 
in those nations.[125, 212, 215] Internationally it has been recognised that there are multiple 
points along the transplantation pathway that need to be addressed  These include; the need 
for high quality ethnicity data  collection to ensure accurate monitoring of equitable service 
provision, a culturally aware and safe health workforce and service reorganisation, including 
funding equity that targets service inequity. Research has shown, that the changes to 
transplantation policy need to be monitored to ensure further extenuation of disparities does 
not occur.  Addressing  transplantation inequity requires a multifaceted approach, that 
requires critical recognition of the health systems role in perpetuating inequities.[216]   
 
This study highlighted perpetuated inequities experienced by Māori and raises questions 
regarding the health system's ability to recognise, reflect, and address systemic structures that 
continue to disadvantage marginalised populations with known health inequities. In order to 
address inequities effective monitoring systems, need to be insitu to identify systemic 
failings. Access to activation on the waiting list and ultimately transplantation was greater for 
non-Māori even when adjustments were made for age, smoking status, deprivation and BMI. 
There is an identified need for effective, timely communication in the information provided 
to the patient regarding the disease progression of CKD, and information available to whānau 
and friends regarding organ donation awareness and knowledge.[123, 217] Based on the 
findings in the present study, potential actions to address persistent inequities in kidney 
transplantation might include; timely intervention that is inclusive of cultural values and 
beliefs to increase equitable access to kidney transplantation, including the mandatory 
offering of pre-emptive transplantation as an available and accessible treatment through live 
organ donation.[218]   
 
Previous studies have identified that for Indigenous Peoples with kidney disease, there are 
specific concerns regarding access to culturally appropriate care, miscommunication, and fear 
of mainstream health services.[115, 118, 119]  Researchers have identified Indigenous 
traditional values and beliefs associated with 'intact body' at death as possible transplantation 
barriers.[219] However, patients' traditional beliefs and values should never be assumed, nor 
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should clinician bias and lack of understanding of Indigenous values be tolerated.[102, 140] 
Information regarding transplantation as a treatment option should be provided in a manner 
that supports informed decision making and explores the benefits of transplantation, whilst 
recognising specific Indigenous beliefs.  The health system should build on health research 
that has explored both Indigenous beliefs and rates of transplantation to develop processes 
that ensure equity of provision of kidney transplantation. 
 
Potential actions to address identified barriers might include building quality improvement 
strategies that identify fragility points for Māori patients to address the increased risk of 
mortality and decreased level of transplantation that Māori patients experience.  This means 
embedding evaluation and health equity measures of quality care into transplantation service 
practices, including research. Identifying high-risk points along the transplantation pathway 
for Māori is one method of including equity measures into the service, this includes 
addressing waitlist suspension.[220]  This may include a quality metric tool that explores 
services and identifies service barriers to access the ‘gold standard’ treatment of 
transplantation. The identification of resource allocation regarding transplantation services 
needs to be addressed at a policy and system level. There should be a critical review of 
services to identify reasons for barriers to equitable care.  Equitable care is quality care, 
inequitable care is unsafe care.  Inequities in kidney transplantation is a system failure and 
leads to increased mortality.  Once inequities are identified and measured accurately they 
then can be addressed, including patient requirements, both laboratory and hospital-based, 
and associated social and financial costs can be assessed and potentially negated by inbuilt 
systemic equity processes. 
 
While the study's strengths included a Kaupapa Māori approach, the inclusion of the 
CONSIDER criteria, an entire population dataset (ANZDATA), the data linkage that enabled 
analysis of length to waitlist and length of waiting list, and Indigenous age standardisation, 
the study has limitations that need to be considered when interpreting the results.  First, this is 
a retrospective study and residual confounding may not be fully accounted for.  Second, this 
study did not explore the reasons for suspension from waiting list, which may be a true cause 
of differences and delays in transplantation.  Lastly, given the small number of events, this 
study did not explore in depth circumstances regarding pre-emptive transplantation access.  
Future research investigating kidney failure inequities could include investigating reasons for 





Using a Kaupapa Māori approach, this study identified that Non-Māori in Aotearoa New 
Zealand are provided with earlier waitlisting for a kidney transplant, higher rates of live and 
deceased donor kidney transplantation, shorter waiting times for kidney transplantation once 
waitlisted and lower mortality prior to kidney transplantation. 
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Table 11 Baseline descriptive characteristics 
Descriptive Characteristics  Māori n=1547  Non-Māori  n=3436 
Age, years (std dev) 55 (14) 57 (16) 
Female(%) 622 (40) 1338 (39) 
Smoking Status (missing data 5) (%)     
Current 380(25) 400(12) 
Former 722(47) 1248 (36) 
Never 442(29) 1786 (52) 
Deprivation NZ13 (%)     
1 to 4  207(13) 1216(36) 
5 to 8 370(24) 1009(30) 
9 and 10 969(63) 1150(34) 
Domicile     
Urban  1037(67) 2735(80) 
Independent  284 (18) 314 (9)  
Rural  212(14) 225(7) 
Missing     
First Vascular Access (H.D.) (%)     
Native 279(18) 584(17) 
Non Tunnel CV Catheter  490(32) 859(25) 
Synthetic  18(1) 23(1) 
Tunnel CV Catheter 326(21) 715(21) 
Late referral (%) 344(22) 604(18) 
Laboratory variables at first access       
Haemoglobin, g/L (std dev) 110(17) 111(16) 
Serum creatinine µmol/L (25th, 75th quartiles)  782(547,926) 724(499,862) 
Panel reactive antibodies (PRA) * (%)  n=85  n=377 
<50% 80(94)   349(93)   
>50% 5(0.3) 28(7) 
Blood groups * (%)  n=382  N=1341 
A  178(47) 512(38) 
AB 11(3) 43(3) 
B 18(5) 178(13) 
O 175 (46) 608(45) 
Body mass index kg/m2 (std dev) 32(8) 27(7) 
Primary cause of kidney disease (%)     
Diabetes     
Type 1  26(2) 117(3) 
Type 2 1032(67) 1086(32) 
Glomerulonephritis 249(16) 953(28) 
Polycystic kidney disease 24(2) 258(8) 
Other * 136(9) 568(17) 
Vascular Hypertension 80(5) 455(13) 
Comorbid medical conditions* (%)     
Cancer  96(6) 327(10) 
Cerebrovascular disease  170(11) 384(14) 
Chronic lung disease  379(24) 473(14) 
Coronary artery disease 590(38) 1127(33) 
Diabetes     
Type 1 26(2) 121(4) 
Type 2 1102(71) 1318(38) 




Figure 8  Proportion (%) of patient (Māori and non-Māori) outcomes by year 
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Figure 10 % of patients who died on waitlist for kidney transplantation & % of patients 










6.6 Chapter Conclusion 
 
This chapter is based on the paper titled “Inequity in transplant related practices and 
outcomes in Aotearoa New Zealand: A Kaupapa Māori analysis” that has been prepared for 
submission to The Journal of Equity and Health.  This chapter demonstrated a Kaupapa 
Māori quantitative approach that identified that non-Māori patients with kidney failure were 
provided with higher rates of pre-emptive kidney transplantation and waitlisting for a 
deceased donor kidney transplant, shorter times to waitlisting and transplantation and higher 
rates of survival prior to and after waitlisting for a kidney transplant in Aotearoa New 
Zealand, even after adjustment for socioeconomic deprivation, comorbidities, body mass and 
smoking history. This chapter provides further evidence of how quantitative methods can be 
used to critically evaluate systems from a Kaupapa Māori perspective.    
 
Chapters three through to six have applied Kaupapa Māori research methods to describe the 
multifactorial causes of CKD inequities, including colonisation, racism, marginalisation and 
inequitable provision of best practice.  In the following chapter (chapter seven) a synthesis of 
the findings from the previous chapters will be discussed, within the context of the United 
Nations Declaration of the Rights of Indigenous Peoples, Te Tiriti o Waitangi and the 
identified research aims of this thesis.   
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Chapter Seven: Discussion 
Article 46  
The provisions set forth in this Declaration shall be interpreted in accordance with the 
principles of justice, democracy, respect for human rights, equality, non-discrimination, good 
governance and good faith. 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
7.1 Introduction 
Article 46 of the United Nations Declaration of the Rights of Indigenous Peoples concludes 
with a clear statement regarding equality and human rights.[1] Whilst the Declaration is not 
legally binding, it does imply the signatories of the declaration agreed to enact equity and 
human rights based principles for Indigenous Peoples.  Therefore, the continual inequitable 
health outcomes for Indigenous Peoples represent a breach to the intent of the declaration. 
This thesis has utilised a case study approach to explore inequities in chronic kidney disease, 
which has identified persistent privileging of non-Indigenous peoples  within the health 
system in Aotearoa New Zealand.  
 
The research aims of this thesis were to undertake:  
1. A systematic literature review with frequency analysis evaluating the practices and 
the findings of epidemiological studies of chronic kidney disease involving 
Indigenous Peoples.  
2. The development of a research reporting guideline to support researchers to develop a 
strength-based approach to health research involving Indigenous communities and 
participants. 
3. A retrospective cohort analysis exploring the potential sources of inequity in dialysis-
related practices and outcomes in Aotearoa New Zealand using Kaupapa Māori 
Research methodology and indigenous statistical approaches. 
4. A retrospective cohort analysis exploring potential sources of inequity in kidney 
transplantation in Aotearoa New Zealand using Kaupapa Māori Research 
Methodology and Indigenous statistical approaches.  
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The findings of this thesis have identified that, for Māori, there continues to be a lack of 
accountability of the Crown to Te Tiriti ō Waitangi  and the intent of the Declaration of 
the Rights of Indigenous Peoples to address pervasive inequities experienced in CKD.  
 
In this thesis, the systematic literature review (chapter 3) highlighted current limitations in 
methodological approaches which reduced opportunities to fully explore causative factors 
related to chronic kidney disease inequities experienced by Indigenous Peoples globally. 
Subsequently, the systematic review lead to the formulation of the CONSIDER statement 
(chapter 4) that proposes criteria to strengthen how studies involving Indigenous participants 
and communities are conducted and reported.   Kaupapa Māori Research methodology 
provides the foundation for this research, including the inequities in dialysis and 
transplantation (chapters 5 and 6) case studies. The reporting of these studies using KMR 
aligned with the key principles of CONSIDER statement. These two chapters document how 
research practices can identify and report the sources that contribute and maintain health 
inequities within Indigenous communities.  These chapters illustrate how colonisation 
informs the current context of both research praxis and epidemiological knowledge.  
 
This purpose of this current chapter is to provide a synthesises of the overall findings of this 
thesis and to present implications for future research and health practices. This chapter will 
discuss the role of research in understanding health inequity, Indigenous rights to equity in 
health and well-being, accountability in action, equity in CKD clinical pathways, and 
research strengths and limitations. 
 
The Role of Research in Understanding Health Inequity 
 
The systematic review (chapter 3) highlighted the dominance of biological processes in the 
explanations of health disparities in Indigenous populations with chronic kidney disease. 
Most existing studies included in the systematic review attributed the causation of chronic 
kidney disease inequitable outcomes in Indigenous populations related to chronic kidney 
disease to biological risk factors.  This has included a strong narrative that biological risk 
factors are highly correlated with increased prevalence of comorbid conditions, especially 
diabetes and heart disease.[221] Some studies reported on the role of genetics as explanatory 
factors of inequity.[222] The systematic review also identified that since 2012 there has been 
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an increase in research exploring the role of colonisation and racism as explanatory factors 
attributing to current CKD inequities.  
 
When the CONSIDER statement was utilised to review the completeness of reporting,  it was 
found that the eligible studies failed to incorporate core principles of Indigenous research to 
inform and/or improve current understanding of disparities, including the impact of 
colonisation and racism. This thesis has identified that a strength-based process could expand 
the research from a focus on biological factors as causes of inequity, to research 
incorporating core principles of Indigenous research, that can account for colonisation as a 
central cause of inequity. These are inclusive of and driven by Indigenous understanding, 
knowledge and experiences that considers racism, social justice and wider socio-political 
factors. This strength based research can inform policy and practices to address health 
inequities, inform new practices and treatments, and does not perpetuate racist stereotypes 
related to biological risk factors. This was highlighted by the findings of the inequities in 
dialysis and transplantation projects completed for this thesis.  
 
Chapter Five applied statistical methods such as propensity score matching and Indigenous 
age standardisation to incorporate Indigenous quantitative research methodologies in order to 
gain an understanding of CKD health disparities with regard to inequity in dialysis treatment. 
A key finding is, that even after matching cohorts were by risk factors (comorbidities, BMI, 
smoking status), primary cause of disease, and socio-economic factors (deprivation, rurality) 
a difference in some practice patterns persisted.  Notably Māori were more likely to receive a 
lest preferred first vascular access than non-Māori, and more likely to die  Similarly, chapter 
six identified that non-Māori were more likely to receive “gold standard” best practice for 
treatment of kidney failure, which is a pre-emptive transplant, were more likely to receive a 
live donor transplant, and less likely to die while waiting for a kidney transplant once 
activated on the waiting list.  
 
Findings from this thesis have identified that the disease and treatment pathway for Māori 
with CKD and kidney failure are different to non-Māori, and places Māori at increased risk 
of mortality.  This thesis has identified that current accepted explanatory factors, namely 
factors related to comorbidities, primary disease and individual behaviours do not explain 
ongoing health inequities.  These biomedical risk factor explanations do not provide rationale 
for the experiences of Māori patients and whānau who suffer from CKD and kidney failure.   
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Research has been completed that provides a descriptive analysis of the impact of 
perpetuating inequities on Māori patient’s and whānau by providing the patient’s narrative. 
The study by walker documented the impact of disempowerment, low self-esteem, 
embarrassment, limited acknowledgement of impact of intergenerational experience of 
disease, limited engagement with whānau, and the stigma of kidney disease.[115] They 
conclude that the identification of a lack of provision of service to achieve health equity 
should be a driver of institutional change.   
 
Similar to the findings of this thesis, the Crown’s provision of health services such as best 
practice treatments (pre-emptive transplantation) in not provided to Māori in an equitable 
manner.  It could be argued that there is a lack of “good governance” related to these known 
sustained health inequities.  As Kukutai, Walter and Russo Carroll (2020) state the 
normalisation of failure within the state-run system is not the focus of scrutiny, but rather the 
expectations of health failure on certain groups are normalised and expected without 
repercussions. [41] 
7.2 Indigenous rights to equity in health and well-being. 
 
Research focussed on health inequity concludes that colonisation is the common explanatory 
experience of Indigenous Peoples whom experience health inequities in their own countries. 
[2, 11] However, the invisibility of the impact of colonisation on health inequity of 
Indigenous Peoples by Westernised Medical/ Biomedical research remains entrenched.[41] 
Indigenous scholars and Indigenous health advocates note the important role that research has 
to monitoring Crown responsiveness to reduce those factors that perpetuate health inequities 
for Indigenous peoples.[17, 55] This thesis has identified that future research of health 
inequities experienced by Indigenous Peoples must include interpretations and analysis that 
acknowledge the role of colonisation and racism, on the health and well-being of Indigenous 
Peoples globally.  This extends to policy, procedures and agencies of the Crown who 
continual fail to meet Te Tiriti o Waitangi principles, basic human rights principles of the 
right to good health, equal opportunities and the UN Declaration of the rights of Indigenous 
Peoples to equality, non-discrimination, good governance and good faith. [1] Identification of 
how research is used to describe and identify causative influences of Indigenous Peoples 
health outcomes must be critically reviewed, including who is completing the research, how 
they have analysed the data and do they represent the best interests of Indigenous Peoples. 
The monitoring of discrimination and inequity through research, provides a mechanism to 
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ensure the rights of Indigenous Peoples, as stated in the UN Declaration of the rights of 
Indigenous Peoples, and more specifically for Māori the Crowns Te Tiriti obligations.  
 
Within Aotearoa New Zealand, the inequities experienced by Māori patients and whānau 
within the health system can no longer be accepted.  As identified within this thesis the 
economic, social, political, justice and health systems must address inequities experienced by 
Māori in Aotearoa   Increasingly society ‘norms’ in relation to inequities experienced by 
minority populations are being scrutinised and re-presented from the position of those who 
the system disadvantages.[223]  In Aotearoa this has enabled self-determination discourse 
which refutes that colonial discourse which has perpetuated systemic bias.[17]The findings of 
this thesis argue that the relationship between research, health policy and clinical practice 
must be scrutinised, with clinical practice being informed by health research.  Research has 
immense implications for the way that health policy and ultimately clinical practice is 
informed.  The following section provides discussion points related to the implementation of 
Tino Rangatiratanga principles to research and clinical practice pathways.  
7.3 Accountability in Action 
 
Article 46 of the Declaration of Rights of Indigenous Peoples discusses good governance and 
equality.  Good governance requires an understanding of current and historical context, and 
partnership between all stakeholders. Good governance must critically reflect on “the state’s 
ability to serve its citizens”. [224] The health system and research institutions are agents of 
the state and therefore by proxy are agents of the Crown. Article 3 of Te Tiriti o Waitangi 
stipulates that the Crown agrees to provide protection and full citizenship for Māori. The 
health system and research institutions have a Tiriti obligation to ensure that good 
governance supports the identification and elimination of health inequities.  Research 
institutions must provide research governance, including the monitoring of the institution and 
its researcher’s ability to “serve its citizens”. This research has identified that there is 
minimal reporting and accountability by research institutions to review how researchers are 
working with Indigenous stakeholders. As this thesis has demonstrated, there are numerous 
research guidelines and ethical principles available to researchers; however, there is still a 
lack of governance accountability regarding how Indigenous stakeholders in research are 




Academic institutions have a responsibility to lead social accountability reform, build 
relationships with Indigenous stakeholders and promote Tino Rangatiratanga principles.   
Failure to do so further ‘contains’ health and social inequities to being a “Māori Problem” as 
opposed to being a collective responsibility. Mechanisms that monitor responsiveness to 
Indigenous communities must be a priority for academic institutions that promote, and 
support, researchers whom wish to research health inequities experienced by Indigenous 
Peoples. It is no longer acceptable for academic institutions to knowingly promote research 
that explores Indigenous Peoples without first ensuring the suitability, acceptability and 
accountability of the research. [17, 55]  
 
This thesis promotes the application of the Consolidated criteria for strengthening the 
reporting of health research involving Indigenous Peoples (CONSIDER). The CONSIDER 
statement has been included in the EQUATOR Network guidelines, has had 16 citations 
(Google Scholar), and has been adopted by the Australia and New Zealand Journal of Public 
Health standards to improve the reporting of Indigenous public health research and practice. 
[225] The CONSIDER statement identified that there was a dissonance between research 
ethics guidelines and research reporting. Research institutions and researchers need to work 
towards demonstrating the 17 criteria of research reporting when conducting research 
involving Indigenous Peoples.  CONSIDER identified a lack of consistency in the application 
of best practice in research that involves Indigenous peoples. This must include reference to 
Indigenous worldviews, specific to communities of interest. Likewise, research institutions 
must ensure that there is equity in the pathways of academic progression for Indigenous 
researchers; this includes the valuing of Indigenous worldviews within the academic system. 
The CONSIDER statement demonstrated the limitations of ethics guidelines standing 
independently of fundamental system reform. This research suggests that government funders 
and government-appointed ethical bodies and research institutions must develop a “research 
loop” to ensure no potential harm is caused through the research process. A recommendation 
for research and funding bodies is that they must commit to holding to account any research 
that is completed within Indigenous communities.  
 
This thesis has highlighted the important role of Indigenous methodologies and statistical 
methods to reduce the impact of colonial and racial bias within the analysis of data about 
Indigenous Peoples and CKD. Through the application of CONSIDER criteria and analysing 
data from an Indigenous equity viewpoint, disparities along the transplantation pathway and 
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in dialysis treatment were discovered.[56] Research methods should challenge the 
understanding about health inequities, particularly related to broader understanding of 
chronic disease inequities experienced by Indigenous Peoples.[16] The overarching 
methodological framework of KMR has meant that data analysis within this thesis was 
completed from a Tino Rangatiratanga perspective. This has included using Māori as the 
reference group, applying Indigenous age standardisation, critically reflecting on ethnicity 
data collection practices in large data sets and the application of data principles inclusive of 
colonisation and racism as influential systemic cofounders.  
In order for research to understand health inequities experienced by Indigenous Peoples, all 
areas of research, must be seen as Indigenous research.   
 
This thesis has promoted the role of research partnerships between researchers and 
Indigenous communities to reduce health inequities in CKD.  Research institutions must 
support Indigenous researchers and communities to regain control over the way Indigenous 
health is portray via all levels of research.  Research institutions have a responsibility to 
ensure that researchers are not only held accountable for research that involves Indigenous 
stakeholders, but also, they are held accountable for the way that the research portrays health 
inequities experienced by Indigenous Peoples.  Research institutions need to develop research 
partnerships with Indigenous communities’ that identify research priorities, as well as 
critically appraises research outputs to ensure that research does not continue to perpetuate 
stereotypes. The outcomes of meaningful relationships may include supporting academic 
pathways for Indigenous researchers, engagement with Indigenous communities, identifying 
research outputs that place scrutiny on the health system.    
 
This thesis has highlighted the need for future research investigating CKD and Indigenous 
Peoples.  The systematic literature review undertaken for this thesis identified that there is a 
clear understanding of biological factors associated with current CKD disparities experienced 
by Indigenous Peoples. It also identified a growing understanding of the role of socio-cultural 
factors such as colonisation and racism on health inequities experienced by Indigenous 
Peoples.  This growing understanding also enables identification of possible interventions 
that are strength based and inclusive of Indigenous worldviews.  Future research investigating 
CKD and Indigenous Peoples should build on the growing understanding of the impact on 
determinants of health on health outcome, and embrace action-based research practices that 
involve partnerships with Indigenous communities. Research partnerships should inform 
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health service reform and ultimately improvement of health service delivery to Indigenous 
Peoples.  
 
This thesis has promoted the importance of the relationship between research and health 
service delivery in order to address health inequity in CKD.  Given that research informs 
practice, the impact of research that perpetuates health stereotypes associated with 
Indigenous Peoples, and more specifically Māori on health service delivery is evident. Both 
quantitative and qualitative research that is grounded in principles and values of KMR to 
support Māori health outcomes is more likely to develop both policy and clinical care 
responses that will reduce health deficits.[26] 
7.4 Equity in CKD Clinical Pathways 
This thesis has identified that at a policy level within Aotearoa/New Zealand there is a need 
to ensure that clinicians and health services are able to deliver ‘best practice’ care and 
treatment chronic kidney disease and kidney failure to all people living in Aotearoa New 
Zealand.  Currently only very few pre-emptive transplants completed on an annual basis in 
Aotearoa.[70] Transplantation provides the best outcome for patients, however barriers such 
as cost, organ and service availability are still significant barriers to treatment for all New 
Zealanders.[207] A number of reports to the Ministry of Health have argued for more 
Ministerial funding to enable services to meet transplant demands, and the demands placed 
on dialysis services. Māori are further disadvantaged within this under resourced service. 
This thesis also demonstrated that within earlier stages of the disease different care patterns 
result in a higher burden of disease outcome such as mortality.  Best practice pathways are 
well understood within renal replacement therapy.  It is disheartening to consider that the 
impact that service delivery is having on Māori patient outcome.   
 
This thesis advocates for equity audits within CKD services by ethnicity. Health services can 
no longer continue to “accept” that the health of non-Indigenous Peoples will be better than 
the health of Indigenous Peoples.  There is a need for health services to identify inequity in 
order to design system responses that address inequity.  In order to do this, services must 
regularly perform equity audits and formalise key equity targets.  An example of this for 
CKD services would be to include equity audits as an essential part of service improvement 
strategies.  This would include auditing regional and national renal services by ethnicity and 
with identified outcome targets.  An example of this would be rates of transplantation. 
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Currently limited number of kidney transplants are performed annually in Aotearoa.  An 
equity of access to best practice approach would be to ensure that Māori are transplanted at 
an equal proportional rate to non-Māori, including live donor transplantation.   
7.5 Research Strengths and Limitations 
A strength of this thesis comes from the alternate (other than a western biomedical paradigm) 
perspective of data and health disparities because it provides a critical reflection of current 
health status experience by Indigenous Peoples. As an Indigenous researcher I have an 
‘insider’ perspective related to Indigenous Peoples and current health disparities. As such, my 
perspectives and choices of methods are driven from my Indigeneity. It is this standpoint as 
an Indigenous quantitative researcher that provides Tino Rangatiratanga over the way that 
information has been gathered, analysed and discussed within this thesis. As an Indigenous 
researcher the ability to draw on the research and language that aligns with Indigenous 
academics provided a critical approach that is recognised globally through Indigenous 
research networks. This included the application of quantitative methods from an Indigenous 
research perspective, such as Indigenous age standardisation, the prioritisation of ethnicity, 
the data linkage of datasets that enabled analysis to include deprivation and the use of 
propensity score matching. The ability to enact principles of Indigenous data sovereignty was 
also a strength of this study, this included the acquisition and analysis of Indigenous data, by 
an Indigenous researcher.  The enactment of Indigenous data sovereignty principles informed 
the systematic literature review and the critique of reporting practices of research exploring 
inequities in CKD experienced by Indigenous Peoples.  As well as the development of the 
Consider statement.  
 
While this thesis draws on global principles of Indigenous data governance, sovereignty and 
Indigenous quantitative methods, the data is specific to Māori patients and whānau based in 
Aotearoa.  There are identified similarities related to experiences of health inequities, CKD, 
kidney failure and the impact of colonisation and racism on health outcomes, there are 
however contextual differences that need to be accounted for when interpreting the results.  
These include: 
• The embedding of Te Tiriti o Waitangi in legislation, including health legislation and 
policies in Aotearoa is a different experience to other Indigenous peoples.   
• The geographical differences between Aotearoa and other countries such as Canada 
and Australia and the impact that rurality has on the Indigenous peoples of those 
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nations. This includes the impact rurality has on access to ESKF treatment and renal 
replacement services.  
• Country specific differences in health service delivery.  In United States of America 
and Canada the health system is structured differently than Aotearoa. An example of 
this is Aotearoa has the highest rates of home dialysis that any other country.   
 
There are limitations related to case study design, including bias associated with retrospective 
data, the limitations of the datasets analysed to fully capture the higher exposure to risk 
factors such as racism and colonisation, unable to account for residual confounding, no 
known Indigenous sovereignty principles applied at data collection, and limited evidence that 
the research was prioritised by Māori communities. Future research should include capability 
to assess community prioritisation of the research.        
7.6 Chapter Conclusion 
 
This chapter has provided a discussion based on the synthesis of findings of the research 
projects that inform this thesis.  The findings from each of the research projects have 
identified areas within both research and health service delivery that require urgent review.  
This includes the delivery of best practice clinical pathways for Māori patients suffering from 
CKD and ESKF, the need for research institutions to be accountable to Indigenous 
communities including ensuring that research is not perpetuating health inequities and health 
stereotypes that continue to normalise deficit health outcomes for Māori and finally the need 
for all research investigating health inequalities experienced by Indigenous peoples must be 
inclusive of analysis that incorporates the impact on colonisation and racism on Indigenous 
Peoples.   
 
The final chapter in this thesis highlights the novel outcomes of the research projects and a 






Chapter Eight: Conclusion 
 
Article 43 
The rights recognized herein constitute the minimum standards for the survival, dignity and 
well-being of the Indigenous Peoples of the world. 
United Nations Declaration of the Rights of Indigenous Peoples [1] 
 
8.0 Introduction  
 
The combination of the research projects within this thesis has enabled the identification of 
mechanisms that have perpetuated health inequities experienced by Māori with CKD. These 
mechanisms are entrenched in research institutions globally. However, this thesis has 
demonstrated the value of both Indigenous research methodologies and Indigenous research 
principles in addressing current health inequities in Indigenous Peoples. The application of 
Tino Rangatiratanga principles has enabled the development of new knowledge to support 
health equity research.  
8.1 Tino Rangatiratanga in Health Research 
 
This thesis has incorporated the principles of research Tino Rangatiratanga in order to 
identify causative factors that contribute to CKD inequities experienced by Māori patients 
and whānau. The thesis has identified the evolution of research methodological approaches 
that have influenced how health inequities have been researched and framed. 
The projects of this PhD thesis have identified important gaps (CONSIDER checklist) within 
global research practice with Indigenous Peoples, and have demonstrated the value of 
quantitative methods in the identification of persistent causative factors of health inequities 
experienced by Māori with CKD in Aotearoa. The implementation of Tino Rangatiratanga 
practices within this thesis provides an example of how research of health inequities 
experienced by Indigenous Peoples must involve Indigenous health leadership and research 
partnerships with Indigenous communities to ensure that research is not playing a significant 
role in perpetuating inequities, health stereotypes and racism. 
 
In order to address inequities, there must first be an acceptance from health, education and 
socio-political structures that have perpetuated the notion of “white superiority”, as supported 
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by Darwinism. Colonial socio-political viewpoints continue to be the most influential with 
respect to how knowledge is gained and disseminated.[41, 223]  This includes health 
research.  In order to move forward and gain traction in addressing health inequities there is 
an urgent need for Indigenous and minority perspectives and knowledge to be of equal value. 
The outcomes of this thesis have developed a set of criteria that support the development and 
implementation of Indigenous perspectives.  
 8.2 Novel outcomes of this research 
There is a significant amount of research that has been completed investigating CKD in 
Indigenous populations. The methodological approach of this PhD has meant that there have 
been novel outcomes generated. Firstly, the development of the Consolidated Criteria for 
strengthening reporting of health research involving Indigenous Peoples: The CONSIDER 
statement. The CONSIDER statement is a consolidation of ethics and research principles for 
working with Indigenous Peoples to support researchers to produce research that does not 
perpetuate inequities. The CONSIDER statement was applied to CKD literature as an 
Indigenous critical construct to assess the completeness of studies investigating CKD and 
Indigenous Peoples, as well as identifying future research approaches that could improve 
understanding of CKD in Indigenous Peoples and provide solutions in current inequity.  
 
Secondly, the use of Indigenous quantitative methodologies has meant that this research has 
identified significant differences in clinical practice patterns related to Māori experiences of 
dialysis and transplantation. These findings could have an influence on future approaches to 
Indigenous Peoples suffering from CKD, as well as broader applications to chronic disease 
care for Indigenous Peoples. This approach informed ANZDATA representatives of the 
incongruent methods of collecting information regarding ethnicity, (in relation to New 
Zealand health research best practice) and led to a change in protocol for ethnicity data 
collection via ANZDATA, driven by the ANZDATA Indigenous working group. The use of 
statistical methods such as propensity score matching (using the Māori population as the 
reference cohort), and Indigenous age standardisation identified the impact of different 
practice patterns on Māori patients’ mortality.  
8.3 Mauri Ora 
 
In chapter one of this thesis the United Nations Declaration of the Rights of Indigenous 
Peoples outlines that “States shall take the necessary steps with a view to achieving 
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progressively the full realization of this right.”[1]  Currently it could be argued that states are 
not taking the necessary steps to achieve health and well-being in Indigenous Peoples.  The 
aim of this thesis was to utilise Indigenous methodological pedagogies to critically 
investigate the multifactorial causes of CKD inequities, including investigating the impact of 
colonisation and racism.  Utilising a Tino Rangatiratanga approach this thesis has identified 
that research that fails to consider colonisation and racism as significant contributing factors 
to health inequities not only continues to ignore the basic human right of health and well-
being for Indigenous Peoples, but also perpetuates inequities that ultimately, in their most 
extreme form can kill.   
 
This thesis has demonstrated that if research and health systems continue along the status 
quo, without any consideration for roles and responsibilities in relation to health equity, 
Indigenous Peoples will continue to experience the worst health outcomes in their own 
nations.  It is no longer acceptable for research and health systems to ignore health inequities, 
or worse identify health inequities but continually fail to address them.  Research and health 
systems must respond to the United Nations Declaration of Indigenous Rights statement that 
equity is a minimum requirement and long term equitable well-being is the goal. Likewise in 
Aotearoa, the health system response and research that informs the health system response, 
must be at a minimum, inclusive of Te Tiriti ō Waitangi principles including Tino 
Rangatiratanga.  Implementation of principles of partnership should be a priority for health 
systems and research institutions.  Indigenous Peoples suffering from CKD, kidney failure, 
and more broadly chronic health conditions, generally should have identified care pathways, 
informed by research led by, or in partnership with, Indigenous researchers and communities. 
This ensures that at a minimum Indigenous Peoples will have the same disease trajectory and 
access to kidney transplantation as non-Indigenous Peoples.  The fact that Indigenous Peoples 
have the highest rates of disease and mortality, but the lowest rates of access to best practice 
treatment should be alarming to health and research institutions.   
 
The outcomes of the projects of this thesis have identified that normalisation of disease 
outcomes for Māori is evident.  It is not acceptable that Māori health disparities are accepted.  
Future focus must be inclusive of Indigenous research principles and praxis in order to gain 
understanding and address health inequities in the provision of service to address CKD and 
kidney failure, and more broadly in other health conditions. Implementation of partnership 
led solutions are required in order to develop research and clinical pathways that monitor the 
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Crown, acknowledge the impact of colonisation on health outcomes and are responsive to 
Māori patient’s and whānau.  Equity in outcomes is not the end goal, elimination of the 
impacts of colonisation and racism on the health and the long term well-being of Indigenous 
Peoples is the end goal.  Health research and health systems must continue to strive to 
address inequities by monitoring provision of best practice, as well as identifying provision 
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ANZDATA Information Sheet  
 
Introduction – Why are you being given this Information Sheet?  
You are receiving dialysis or a kidney transplant. This means your health information can be 
collected by ANZDATA.  This information sheet explains what ANZDATA does, and why 
information about you is being collected by ANZDATA.  
 
What is ANZDATA and what does it do?  
“ANZDATA” stands for The Australia and New Zealand Dialysis and Transplant Registry. 
ANZDATA collects information (data) about the health of all people (adults and children) in 
Australia and New Zealand who have kidney failure and have either dialysis or a kidney 
transplant. 
 
ANZDATA is paid for by the Australian and New Zealand Governments, Kidney Health Australia 
and the Australia and New Zealand Society of Nephrology, and has one office that is located in 
Adelaide.  
 
How does ANZDATA collect and store my information?  
Every year, your hospital completes a survey about your health and kidney failure treatment and 
sends this information to ANZDATA either by computer or by post. ANZDATA keeps this 
information about you and your kidney treatment in a highly protected computer network in 
South Australia. There is a lot of security in place to protect your information.  
 
What information does ANZDATA collect about me?  
Your hospital gives ANZDATA your name, postcode, date of birth, gender, ethnic background 
(your race), and information about your health conditions (what diseases you have), details 
about the type of kidney treatment you are receiving (dialysis or transplant) and some of your 
test results and medications. This information is collected when you start dialysis or have a 
transplant, and then every year. Sometimes, extra information will be collected during the year 
as well if something important happens to you. 
We DO NOT collect other personal details about your address, telephone number, Medicare 
number, medical insurance, or non-medical matters such as occupation or income.  
 
How does ANZDATA use my information?  
The information collected by ANZDATA is used for many different things. Here are the main 
ways we use your information. 
1. Making reports with the latest information about patients with kidney failure 
2. Sending reports back to each hospital and telling them how their patients are doing 
NOW compared to the past, and also compared to other hospitals 
3. Understanding the quality, type and place of care people receive  
4. Understanding the type of kidney disease people get, and how they are treated  
5. Understanding how many people have kidney failure and what health care they need, so 
that the best health care services can be set up to look after them  
6. Helping people do research so they can understand more about kidney failure and the 
best ways to treat it and keep patients healthier.  
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* represents mandatory fields required to be collected to create a new registration on the database, however all data is required for the 
registration process to be complete 
NEW Patient Registration 
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